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(X volume fraction of proteins [L/g] 
(I) blood channel width [em] 
l' viscosity [mmHg ·min] 
AI integration constant [] 
A2 a constant [] 
c. solute concentration in dialysate [mmol/L] 
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em solute concentration in membrane [mmol/L] 
cp solute concentration in plasma [mmol/L] 
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Clcavhd clearance rate by CA VHD [ml/min] 
~ plasma protein concentration [g/dl] 
Cpa initial plasma concentration [mmol/L] 
~ot-a plasma protein concentration at filter inlet [g/dl] 
~. plasma concentration after a time span t [mmol/L] 
S>rot-v plasma protein concentration at filter outlet [g/dl] 
Cw solute concentration in plasma water [mmol/L] 
f fractional volume distribution of solute in blood cells [] 
F free fraction of a drug [] 
h height of the fluid column in the UF-Iine [em] 
Ht hematocrit [] 
·; at filter inlet [] 
J, solute flux [)llll/min l 
Jv volume flux [)llll/min] 
Kd mass transfer coefficient of diffusion [pm/min] 
K.c mass transfer coefficient of diffusion of creatinine [)llll/min] 
Kdp mass transfer coefficient of diffusion of phosphate [)lll1/min] 
Kw mass transfer coefficient of diffusion of urea [)llll/min l 
Km..x maximal Kd at infinite dialysate flow rate [pm/min] 
L fiber length [em] 
~ hydraulic membrane permeability [em/min • mmHg] 
MAP mean arterial pressure [mmHg] 
MI hydraulic permeability index of the membrane, or 
filter membrane index [ml!h • mmHg] 
MW molecular weight [Daltons] 
Mw total solute mass in plasma water [mmol] 
N number of fibers or blood chanoels of the filter [] 
n KJJv [] 
-. at filter outlet [] 
pb hydraulic pressure in blood compamnent [mmHg] 
pd hydraulic pressure in dialysate compamnent [mmHg] 
P;a hydraulic pressure in the artety [mmHg] 
piv hydraulic pressure in the vein [mmHg] 
P. hydraulic pressure in the arterial line [mmHg] 
pv hydraulic pressure in the venous line [mmHg] 
Qb blood flow rate [ml!min] 
Q, ultrafiltration flow rate [ml/min] 
Q. dialysate flow rate [ml!min] 
Qw plasma water flow rate [ml/min] 
Qpa artetial plasma flow rate [ml/min] 
Qpred predilution flow rate [mllmin] 
r radius of the fiber of the filter [pm] 
R total resistance to diffusion [min/pm] 
R,. resistances to flow of the arterial access [mmHg · min/ml] 
Rb resistance to diffusion in blood compartment [min/pm] 
Rd resistance to diffusion in dialysate compartment [min/pm] 
Rr resistance to blood flow of the filter [mmHg . min/mll 
Rm Rf corrected for blood viscosity (RJ)l) [lo'/ml] 
R,. resistance to diffusion in membrane [min/pm] 
R.. resistances to flow of venous access [mmHg . min/ml] 
s sieving coefficient [] 
s membrane surface area [mz] 
I time [hr] 
TMP transmembrane pressure [mmHg] 
T~ drug half life (hrs] 
vz volume of distribution [L/kg] 
w width (S!L) [m] 

CHAPTER 1 
INTRODUCTION 
THE DEVELOPMENT OF BLOOD PURlFlCATION TECHNIQUES 
History 
The history of blood purification started with the judgement of different body fluids 
by color and consistency. Blood leuing, as popularized by Hippocrates (460-377 
B.C.), was one of the most common therapeutic tools in antique medicine. HistOry 
tells us that too much blood leuing was weakening the Spartan army and may very 
well have contributed to its defeat by the Athenians. 1n the 17th and 18th century, 
blood purification was achieved by adequate purgation every week, application of a 
strong emetic once a month, and blood leuing twice a year, in spring and fall. 1n 
1854, Graham demonstrated that a vegetable parchment, sealed with albumin, acted 
as a semipermeable membrane. When he placed a fluid, containing crystalloids and 
colloids, on one side of this membrane, he found that only cristalloids diffused 
through the membrane. He named this phenomenon dialysis [1]. 
1n 191 I, Haas in Giessen, Germany, who was confronted with numerous cases 
of 'field nephritis', first tried to petform dialysis of the blood in uremic patients. In 
1913, Abel reported the first successful dialysis on a live animal. 1n 1924, Haas 
petformed a 15 minute dialysis in a uremic patient, by using a celloidin membrane. 
Two further developments were very important for the development of dialysis, i.e. 
the discovery of heparin in 1918 and the manufacturing of cellophane membranes in 
the 1930's, which were used as package material for sausages. Using this material, 
Kolff, in 1943, treated his first patient in Kampen, the Netherlands, with his rorating 
drum dialyzer. Blood access was obrained by arteriotomies and venesections, which 
limited the number of dialysis treatments in one patient His 17th patient was the first 
that survived. This patient was the first human being whose life was saved by 
dialysis [2]. 
Duling World War II, the hundreds of patients with renal failure from crush 
injuries instigated further developments. Alwall, in Sweden, stressed the importance 
of fluid overload. He devised a 'dialyzer-ultrafilter' in order to petfonn ultrafiltration. 
1n 1947, Malinow, in the USA, in an experimental study of dogs, produced 
ultrafiltrate from blood and replaced it with Ringers solution [3], thereby cleaning the 
blood. This was the first description of hemofiltration. 1n 1948, Kolff was invited to 
New Yorlc to continue his work in the United Srates in cooperation with Merrill. By 
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1952, Merrill reponed that about 45 rotating drum dialyzers were in use in 1he 
United States, mostly for the treatment of acute renal failure. A few years later, 1he 
Baxter company staned the commercial manufacturing of dialysis equipment. In 
1960, Quinton and Scribner described a method for the chronic cannulation of blood 
vessels by the use of a teflon tubing by-pass of 1he anery and vein [1]. Both these 
developments made an enormous contribution to the spreading of the dialysis 
technique. 
Mechanisms of solute transport and terminology 
Nowadays, hemodialysis and hemofiltration are commonly used blood purification 
techniques. With both techniques, blood is led through a flat sheet or a capillary 
dialyzer. The dialyzer consists of a blood and an ultrafiltrate/dialysate companment, 
separated by a membrane. The membrane is permeable to solutes of up to several 
thousand Daltons, dependlug on the membrane pore size, but not to proteins and 
blood cells. By virtue of the difference in hydrostatic pressure on both sides of the 
membrane, plasma water leaks through 1he membrane (ultrafiltration) (see Figure 1). 
If solutes have a molecular weight far below the 'cut-off' point of the membrane, 
they can pass the membrane together with the plasma water, so their concentration 
in the ultrafiltrate will be equal to that in plasma water. This transport is called 
convection. Therefore, for these solutes, the convective transport rate is determined 
by the rate of ultrafiltration alone. illtrafiltration does not affect the concentration of 
the solute in plasma water. Only if the ultrafiltration fluid is replaced with a clean 
substitution fluid, the solute concentration in the plasma water falls. This technique 
is called hemofiltration (see Figure 2) and is performed either intennittent or 
continuous. Another way to clean the blood is by ruoning a clean fluid through the 
dialysate comparttnent so as to cause diffusion of solutes from plasma water to 1he 
dialysate companment. This technique is called hemodialysis (see Figure 3). The 
diffusive transport rate is largely determined by the molecular size. Thus, the 
transport of small molecules is favored by hemodialysis whereas that of large 
molecules is favored by hemofiltration. With intennittent hemodialysis, it is now 
common practice to use a high dialysate flow rate (500 ml/min) and it is possible to 
realize a fixed ultrafiltration flow rate, adjusted to the patient' overweight. Therefore, 
a relatively small convective transport occurs too, which can largely be neglected 
when compared to the large diffusive transport. The combination of hemodialysis and 
hemofiltration, in which both modalities function as major transport mechanisms, is 
called hemodiafiltration (see Figure 4), also performed either in the intermittent or 
continuous mode. 
2 
Chapter 1 
Ul TRAFIL TRA TION 
Figure 1. A schematic drawing of ultrafiltration. No clearance of solutes passing the 
membranes will occur as solute concentration in plasma water does not 
decrease. This method is used to witJuiraw an excess of body fluid. 
substitution 
HEMOFIL TRA TION 
Figure 2. A schematic drawing of he11U)filtration. Solutes drawn here, have a 
11U)lecular weight far below the cut-off point of the membrane. Therefore, 
solute concentration in the ultrafiltrate compartment will be the same as 
that in plasma water. Transpon of solutes is by comection. Substitution 
fluid is used to decrease the solute concentration in blood and to impede 
too much fluid withdrawal. 
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Figure 3. A schematic drawing of hemodialysis. Dialysate flows countercurrently 
through the dialysate compartment, which causes a solute concentration 
difference over the membrane. Transpon is by diffusion. 
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HEMODIA-
FILTRATION 
Figure 4. A schematic drawing of hemadiafiltration. Both by convection, by a high 
ultrafiltration flow rate, and by diffusion, by using dialysate, solutes are 
removed from biood. Both convection and diffusion contribute significantly 
to solute transport." 
• 
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Figures 1-4 reprinted with permission from NTVG 1992, 136: 561-565 (see list of 
publications nr. 8) 
Chapter I 
Further refinement of the blood purification techniques 
In the early years of dialysis, patients were treated for 8 to 12 hours, two to three 
times a week. Understandably, the developments in those days were aimed at 
improving the efficiency of the treatment so as to reduce treatment time. 
Accordingly, dialysis membranes became thinner and larger and blood and dialysate 
flow rates were increased. In 1964, however, the drawback of this development 
became clear when Peterson described acute encephalopathy during dialysis 
treatment. This was explained by the rapid fall in the concentration of solutes in 
plasma due to diffusion, leading to an osmotic 'disequilibrium' between plasma water 
and the brain tissue [4]. Dialysis induced hypotension was another frequent 
complication. In 1967, Henderson promoted hemofiltration [5]. With hemofiltration 
the efficiency of the removal of urea was lower but disequilibrium was seldom seen 
and blood pressure was more stable. Moreover, as Babb [6] pointed out, so called 
'middle molecules', which were believed to contribute to the uremic syndrome, were 
removed more efficiently with this technique. This middle molecule hypothesis also 
led to the development of peritoneal dialysis techniques. 
For hemofiltration, new membranes were developed, which allowed passage of 
water and solutes of up to several thousand Daltons at very low pressures. At the 
same time, hemodialysis was refined by controlled ultrafiltration, by the use of 
bicarbonate rather than acetate as a buffer substitute and by the use of higb or 
variable sodium concentrations in dialysate. By virtue of these developments, most 
patients with chronic renal failure can now adequately be treated by intermittent 
hemodialysis in two or three sessions of 410 5 hours a week. In case of acute renal 
failure, however, many problems remained to be solved. 
Continuous arteriovenous hemodiaftltration 
Acute renal failure often results from sepsis, a clinical syndrome that is accompanied 
also by massive edema and circulatory insufficiency, respiratory failure and 
sometimes neurological damage [7, 8]. Patients with acute renal failure are 
characterized by a higb catabolic rate and therefore need intensive dialysis treatment. 
The combination of low or unstable blood pressure and edema makes it qnite 
difficult to judge how much flnid should be withdrawn. The combination of 
ultrafilttarion and hemodialysis frequently leads to hypotension and neurological 
deterioration and may further jeopardize kidney function [9]. Furthermore, rapid 
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correction of the acidosis together with the rise of inflammatory mediators that 
results from the blood-membrane interaction may aggravate respiratory failure [10-
15]. Consequently, in many patients with acute renal failure, 'conventional' 
hemodialysis is contraindicated. Therefore, this group of patients demands a differem 
approach [16]. The prerequisiteS that must be met by the trealment can be summarized 
as follows: 
l. It must be possible to stan trealment at any time; 
2. It must be a very gradual treatment, so as to avoid sudden disturbances in the 
delicate equilibrium and fluid status of the patient; 
3. It must be very efficient in order to treat the uremic syndrome. 
In 1977 Kramer published a method to treat massive ove!h.ydration. He used a small 
dialyzer and conneCted it to ca!h.eters in !h.e femoral artery and vein to obtain a 
spontaneous blood flow driven by the blood pressure of the patiem [17]. No 
substitution fluid was given. This technique is now known as slow continuous 
ultrafiltration (SCUF). Later, in order to comrol the rate of fluid loss, !h.e technique 
was modified by the addition of fluid substitution [18]. In this way, the blood is also 
cleaned. This trealment is called continuous arteriDvenous hernofiltration (CA VH). 
When small highly permeable dialyzers became generally available, an increasing 
number of doctors relied on CA VH for the trealment of critically ill patients with acute 
renal failure. In spite of very low blood pressures, the gradual fluid wi!h.drawal was 
very well tolerated by these patients [19]. As far as the trealment of uremia was 
concerned, the treatment proved to have its limitations. For !h.ese highly catabolic 
patients, the rate of ultrafiltration was seldom enough to provide adequate clearance of 
uremic solutes. Indeed, it was common practice for patients on CA VH to have 
intermittent machine dialysis treatment as well. Several adaptations of !h.e technique 
were suggested. Some advocated the application of a suction pump to the ultrafiltrate 
compartment to increase !h.e ultrafiltration rate [20] whlle others relied on pumped 
venovenous hemofiltration [21]. Kaplan demonstrated the enhancement of the 
efficiency of CA VH by infusing the substitution fluid in the arterial line (predilution), 
rather than in the venous line (postdilution) [22]. Ronco suggested additional dialysis 
with the same dialyzer. He first used a dialysate flow rate of 20 L/hr for 2 hrs a day 
[23] and reasoned that, at a high dialysate pressure, no ultrafiltration would take place. 
The method was, of course, soon abandoned because of the considerable risk of 
'backfiltration'. At the same time Geronemus suggested continuous hemodialysis rather 
than hemofiltration. At a dialysate flow rate of 1-2 L/hr adequate clearance of urea was 
easily obtained. Unfortunately, with the dialyzer he used (a low hydraulic permeability 
of the membrane) the ultrafiltration flow rate was very low [24]. Later he suggested 
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the use of highly penneable membranes [25]. In 1987, Vincent and van Geelen 
presented their first experience in the University Hospital in Rotterdam with continuous 
aneriovennus hemodiofiltration (CA VHD) [26, 27]. They stressed the importance of 
both convection and diffusion [27]. This remarkably simple method, which does not 
require complicated eqnipment or specially trained persontlel, proved both safe and 
very effective. It was soon to become the first choice treatment of acute renal failure 
in the intensive care setting [27-30]. 
Clinical examples 
The following case histories give a picture of the clinical setting in which CA VHD 
treatment is used and show the impact of CA VHD on the treatment of the patient. 
Case 1: 
The patient is a 67 year old man, who had undergone an aneurysmectomy of the 
thoracic aona. The operative procedure had been technically difficult and had lasted 
for 8 hours. During the operation the blood pressure had been very low. In the 
immediate postoperative period, he reqnired ventilatory suppon and despite inotropic 
treatment his blood pressure remained unstable. Urine output decreased to zero. On 
the third postoperative day, the plasma level of urea was 56 mmoi/L, that of 
creatinine was 760 pmoi/L, and that of potassium was 6.2 mmoi/L. There was severe 
peripheral edema and the patient was judged to be oveihydrated. The mean arterial 
pressure was 60 mmHg. Treatment of !he acute renal failure was needed. Because 
of his circulatory instability !he patient was considered to be a poor candidate for 
intermittent hemodialysis and he was treated wiih CA VHD. Caiheters were 
imroduced into !he femoral attery and vein. Treatment was statted at a dialysate flow 
rate of 2 L/hr (1 L/hr is recommended in the standard protocol), because of 
hyperkalemia. On !he first day, a negative flnid balance of 1.5 liter was obtained. 
Urea levels decreased to 38 mmoi/L, creatinine to 450 pmoi/L and potassium to 4.1 
mmoi/L. Dialysate flow rate could be adjusted to 1 L/hr. The following days, urea 
levels stabilized at 20 mmoi/L, creatinine at 210 pmoi/L and potassium levels were 
maintained at 4-5 mmoi/L. The mean anerial pressure increases to 70 mmHg and less 
vasopressor suppon was needed. After two weeks !he patient could be weaned from 
!he ventilator. Finally, on !he 16th day of treatment, !he filter was disconnected 
because renal function had recovered. The patient could then be mobilized. He was 
eventually dismissed from !he hospital after five weeks. 
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Case 2: 
1bis patient was a 59 year old mao, who was admitted to the intensive care unit, 
because of respiratory failure and progressive loss of consciousness. A sepsis 
syndrome was diagnosed but the cause was unknown. Blood pressure was 100/50. 
Ventilator suppon was needed. The hemodynamic and respiratory conditions 
deteriorated rapidly and his condition was further complicated by acute oliguric renal 
failure. The patiem was treated with tobramycin and cefotaxime and large amoums 
of intravenous fluid were administered to maintain adequate blood pressure levels 
and the patients developed massive edema. At the second day, CA VliD treatment 
was staned. Catheters were introduced in the femoral vessels. Dialysate flow rate was 
1 L/br. A net zero fluid balance was almed for. The dose of tobramycin was 
increased to accommodate for the clearance by the dialyzer. To eliminate a possible 
source of infection, the femoral catheters were replaced after a week The condition 
of the patient did not improve. Because the anerial oxygen pressure remained low, 
possibly due to puimonary edema it was decided to withdraw as much as fluid as 
possible. A total of 21 liters were withdrawn over three days. The anerial oxygen 
pressure rose. CA VliD treatment was continued with an average fluid withdrawal of 
1-2 liters per day for 25 days. Ovetall, the dialyzer was replaced 4 limes. Then the 
patient began to pass urioe, his renal function recovered. CA VliD treatment was 
stopped. Ventilatory suppon was still needed. Three days later, symptoms of sepsis 
reappeared. There were signs of pulmonary infection and Pseudomonas aeruginosa 
was isolated from blood cultures. Despite all possible medical suppon the infection 
could not be eradicated and on the 29th day of his iliness the patient died. 
AIMS OF THE STUDY 
As demonstrated by the above examples, in CA VliD blood access is usually obtained 
through femotal catheters, the blood flow rate is not routinely measured and the 
dialysate flow rate is arbitratily set to 1 to 2 L/br. In this way, the treatment proved 
genetally effective. However, sometimes problems were encountered. In some 
patients frequent clotting of dialyzers occurred, probably because blood flow rate was 
too low. Sometimes plasma urea levels did not come down as quickly as we had 
expected or levels of phosphate were found to become too low. There was vinually 
no insight in the determinants of transpon rates and the dialysate flow rate that is 
necessary. It was not known to what extent CA VliD treatment had influence on the 
disappearance rate of drugs. Therefore, in 1989 a study was begun of the 
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detenninams of blood flow rate, ultrafiltration and solute transpon rate in CA VHD, 
so as to be able to optimize CA VHD treaonent. The aims of this srudy can be 
sUllllilalized as follows: 
1. Analysis of the determinants of blood flow rate. 
The resistance to flow rate of catheters and dialyzers was studied and the 
influence of blood viscosity was analyzed. A method was investigated for the 
determination of blood flow rate by using a probe outside the blood line. 
2. Analysis of the determinants of ultrafiltration and convective rranspon rate. 
The transmembrane pressure difference and the hydraulic permeability of 
dialyzers were determined as well as the change in hydraulic permeability over 
time. Funhermore, the 'sieving coefficients' were determined for a number of 
clinically relevant solutes. 
3. Analysis of the determinants of the diffusive transpon rate. 
A mathematical model of combined convection and diffusion was developed and 
used to determine the diffusive mass transfer coefficiem of a number of solutes 
as a function of solute characteristics and operational conditions. 
4. Application of the new knowledge in mathematical models in order to predict 
blood flow, ultrafiltration and solute clearance rates. 
5. Developmem of guidelines for the performance of CA VHD therapy with respect 
to equipment, operational conditions and adjustment of drug dosage and 
additional therapy. 
6. Description of the outcome of patients with acute renal failure, treated with 
CAVHD. 
9 
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CHAPrER2 
PROBLEMS ASSOCIATED Willi INTERMI'ITENT 
HEMODIALYSIS IN ACUTE RENAL FAILURE 
The term acute renal failure is used to indicate the total loss of kidney function 
within hours or days. This is usually caused by acute tubular necrosis, which is in 
fact a misnomer, resulting from ischemic or toxic damage to the tubular cells. It is 
encountered after a period of shock, often associated with sepsis, after aortic surgery 
and after rhabdomyolysis, administration oflarge doses of X-ray contrasl material or 
nephrotoxic antibiotics. Sometimes, acute renal failure is caused by immune complex 
mediated g!omerulonephrilis, resulting from an infection with Staphylococcus or 
Streptococcus species. Most patients in whom acute renal failure occurs are ctitically 
ill and their condition is frequently complicated by multiple organ failure with 
hemodynamic, respiratory or neurological instability. Acute renal failure is a 
potentially reversible condition. After acute tubular necrosis, if the patient's general 
condition improves, recovery of kidney function may be expected after a period of 
two to six weeks [I]. 
In acute renal failure patients, intermittent macltine hemodialysis is relatively 
contraindicated because of the clinical instability of the patient. In tltis chapter a shon 
overview is given of clinical problems encountered with intermittent hemodialysis, 
with emphasis on the possible consequences for critically ill patients. 
Intermittent hemodialysis is a form of renal replacement therapy, that was funher 
developed for the treatment of patients with chronic renal failure. Patients are now 
dialyzed 2 or 3 times a week, for 3 to 6 hours per session. In these few hours, 
clearance rates have to be very high to tide over the interdialytic time interval The 
high clearance rates are obtained by using a large membrane surface area, a blood 
flow rate of 200 lO 300 ml/min and a dialysate flow rate of 500 ml/min. During 
dialysis, flnid is withdrawn 10 an amount adjusted 10 the interdialytic weight-gain of 
the patient. Dialysis treattnent is supplemented by dietary treatment, which at least 
implies restriction of protein and flnid intake. Thus, every means is used to enable 
the removal of uremic solutes and water as fast as possible in the shonest possible 
time. However, there is another side of the coin. 
Over-efficient dialysis is fraught with clinical complications. The most frequent 
complication is dialysis-induced hypotension [2]. It is known from clinical studies 
that rapid fluid removal during dialysis often leads to anerial hypotension. In the 
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early years of hemodialysis, this was atlributed to hypovolemia caused by a fluid 
removal rate that exceeds the rate of fluid mobilization from the interstitial space [3]. 
However, in 1978, Bergstrom et al showed that rapid fluid removal was better 
tolerated if performed without simultaneous dialysis [4]. Also, during simultaneous 
hemodialysis and hemofiltration, removal of water was easier to perform than during 
hemodialysis alone [5, 6]. Furthermore, it was demonstrated that even with 
isovolemic hemodialysis a reduction in blood pressure could be observed [7]. This 
suggested that solute transpon during dialysis interferes with blood pressure control 
and therefore contributes to the side effects of the dialysis treatment. Although this 
phenomenon is still not fully explained, a number of explanations have been put 
forwatd. It has been stated that the rapid fall in plasma osmolality causes a fluid shift 
from the extracellular compartment into the intracellular compartment, the so called 
disequilibrium syndrome [4, 8, 9]. This internal fluid shift together with external 
fluid removal by ultrafiltration results in a decreased intravascular volutne and 
hypotension [10]. Another possible explanation of hypoteusion during hemodialysis 
is an altered response of the autonomic nervous system [II, 12], either because of 
autonomic neuropathy or because of the fall in plasma osmolality. Schultze et al [13] 
have demonstrated that wben using a dialysate containing a sodiutn concentration of 
126 mmoi/L, mean anerial blood pressure dropped 30 mmHg and plasma levels of 
PGE,, PGF20 and plasma renin activity rose significantly in comparison with a 
dialysate containing 140 mmol/L. By using the latter dialysate, blood pressure drop 
was ouly 13 mmHg [13]. Also, the blood-membrane interaction leads to complement 
activation, which, probably through the production of arachidonic acid metabolites, 
causes vasodilatation [13, 14-16]. In general, the risk of dialysis-induced hypotension 
poses no severe restrictions to the treatment of patients with chronic renal failure. In 
hemodynamically unstable patients, however, the risk of hypotension with 
intennittent hemodialysis is often unacceptable. Even with a relatively slow dialysis, 
at a blood flow rate of 180 ml/min, recirculating dialysate and an ultrafiltration rate 
of ouly 200-300 ml/hr, hypotenSion frequently occurs in these patients [17]. 
Another side effect of hemodialysis is hypoxemia. This can be explained by several 
causes. First, in the case of acetate-buffered dialysate, C02 loss into the dialysate and 
a decreased respiratory quotient that results from acetate metabolism will lead to both 
an insufficient respiratory drive andhypoventilarion [18, 19]. Second, hypoventilarion 
may also occur with bicarbonate-buffered dialysate, because of a rapid increase in 
blood pH [18]. Third, membrane bio-incompatibility gives rise to the secretion of 
inflammatory mediators that may lead to pulmonary vasoconstriction [16, 20-22]. By 
using bicarbonate-containing dialysate and more biocompatible membranes (AN-69, 
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polysulfone) rather than cuprophane, these ventilatory problems may largely be 
prevented [20, 22]. 
Hemodialysis may cause neurological deterioration. Patiems may become 
unconscious as a result of uremic encephalopathy itself. Also, the uremic state 
predisposes to the development of seizures [23]. Hemodialysis may, paradoxically, 
impair the neurological condition as a result of sudden changes in pH and osmolality. 
Kennedy et al and La Greca et al have shown that during hemodialysis urea levels 
in cerebrospinal fluid decreased more slowly than plasma levels [24, 25]. Arieff et 
al have shown that in uremic dogs rapid dialysis causes brain edema and seizures. 
Slow dialysis, although resultiog in a similar reduction in urea concentration, was not 
associated with brain edema. The brain edema was caused by a fluid shift resultiog 
from an osmotic disequilibrium between plasma and cerebrospinal fluid. Interestiogly, 
it could be shown that the change in osmolality did not result from changes in urea 
concentration alone. The authors suggested that another, as yet undefined, 
osmotically active solute ('idiogeuic osmoles') is present in the brain, creatiog an 
osmotic gradient between brain tissue and plasma [26]. In a clinical study Port et al 
demonstrated that the first dialysis treannent caused disturbances in the 
electroencephalogram in virtually all patients and subjective symptoms of 
disequilibrium in most of them. They compared two group of patients, one with a 
normal dialysate sodium concentration and one in which dialysate sodium 
concentration had been increased in order to prevent the fall in plasma osmolality. 
They found that by this intervention. neurological problems could be prevented [27]. 
Davenport et al showed that, in case of hepatic encephalopathy, cerebral perfusion 
pressure fell during intermittent hemofiltration treannent but not during contiouous 
atteriovenous hemofiltration (CA VH) [28]. These are indications that, in order to 
prevent neurological complications of dialysis, one should sim for slower solute 
transport rates. Therefore, in patients with neurological problems, contiouous 
treannent methods are preferable. 
In conclusion, rapid removal of solutes and fluids in interntinent hemodialysis has 
some disadvantages. In general, these problems do not impede the treatment of 
chronic renal failure patients. With acute renal failure patients, however, we are faced 
with hemodynamic. neurologic and/or respiratory instability, which is inherent to the 
cause of the renal failure. These problems call for a more restrained approach. i.e. 
by contiouous methods, such as contiouous arteriovenous hemofiltration (CA VH), 
continuous atteriovenous hemodiafiltration (CA VHD) or continuous peritoneal 
dialysis (CPD). With these methods, solute clearance rate is low, which prevent 
osmotic disequilibrium and fluid removal occurs more gradually. 
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CHAPTER3 
THE CLINICAL PRACTICE OF 
CONTINUOUS ARTERIOVENOUS HEMODIAFIL1RATION 
INDICATIONS FOR CAVHD 
In Chapter two !he possible problems with intermittent hemodialysis in acute renal 
failure were discussed. It was concluded that problems encountered with intermittent 
dialysis treanuent of patients with acute renal failure and hemodynamic, neurologic 
and/or respiratory instabiliry call for less vigorous, continuous methods of dialysis. 
Examples of these methods are continuous arteriovenous hemofiltration (CA VH), 
continuous arteriovenous hemodiafiltration (CA VHD) and continuous peritoneal 
dialysis (CPD). Treattuent by CPD will not be discussed in this thesis. As treanuent 
with CA VHD provides higher clearance rates !han with CA VH, optimal treatment 
is by using CA VHD. In !he Universiry Hospital Rotterdam, indications for CA VHD 
are cases of renal failure, complicated by circulatory, respiratory or neurological 
instability, and cases of renal failure for which daily dialysis treatment would be 
needed. In general, patients treated by CA VHD are patients who have had major 
surgery or patients with sepsis and multiple organ failure, including renal failure. 
The combination of renal failure and circulatory instability is !he singie most 
important reason for treatment with CA VHD. The combination of low or unstable 
blood pressure and edema makes it quite difficult to judge how much fluid can be 
withdrawn safely. In cases of compromised myocardial function, vascular refilling 
rate during ultrafiltration is very slow. If such patients were to be treated with 
intermittent hemodialysis, this would lead to ostnotic disequilibrium with further 
impaittuent of vascular refilling. With CA VHD, !he low clearance rates prevent !he 
occurrence of osmotic disequilibrium (I] and fluid removal occurs more gradually. 
Indeed several studies have shown improved vascular stability during treanuent with 
CA VHD [2-6]. 
Respiratory failure or threatening respiratory failure due to fluid overload alone 
are not necessarily indications to use continuous instead of intermittent techniques. 
These patients are best treated with intermittent ultrafiltration. However, if a patient 
with renal failure is weaned from !he ventilator with difficulty, CA VHD is preferably 
to intermittent hemodialysis. The latter may lead to a diminished respiratory drive 
and pulmonary vasoconstriction. This phenomenon is attributed to bio-incompatibility 
of !he membrane [7, 8]. In CA VHD ouly !he more bio-compatible synthetic 
membranes are used. Moreover, with !he longer duration of use, protein adsorption 
to !he membrane minimizes any bioincompatibility effects [9-11]. 
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Neurological instability is another indication for CA VHD. Neurological 
disturbances during intermittent hemodialysis arise from an osmotic disequilibrium 
between blood and cerebrospinal fluid [12-14]. Again, with CA VHD, the lower 
solute clearance rates prevent osmotic disequilibrium. This has been borne out by the 
study of Davenport et al, who showed that in patients with hepatic encephalopathy 
cerebral perfusion pressure fell after intermittent hemofiltration but was preserved 
during treatment with CA VH [15]. 
The indications for continuous treannent mentioned thus far stem from a 
contraindication to intermittent treatment. Another reason to choose continuous rather 
than intermittent treatments is the need for daily dialysis treatment. Acute renal 
fallure patients, especially those with sepsis, are in a hypermetabolic state with fever, 
increased cardiac output and increased resting energy expenditure [16]. Therefore, 
there is an increased demand for both energy and proteins. It has been shown that 
a positive cumulative caloric balance is associated with improved overall survival 
[16-18]. In order to achieve a positive caloric balance, patients often receive total 
parenteral nutrition, which may be complicated by vecy high rates of urea production 
and fluid overload. Until recently, this necessitated daily hemodialysis and 
ultrafiltration. Today these problems are easily managed by CA VHD [19-22]. Indeed, 
Bartlett et al have demonstrated that patients with multiple organ fallure who were 
treated by CA VH showed a more positive energy balance and higher survival rates 
than patients, who were treated by intermittent methods [23]. Compared to 
intermittent hemodialysis, the rate of uremic solute removal is lower inCA VHD, but 
at usual dialysate flow rates the total removal per day is similar. Furthermore, 
intermittent therapies carry the risk of fluid overload in the period between 
successive treatments. This risk is avoided by CA VHD. It must be realized that with 
both treatment modalities amino acids are removed to a certain extent [24-28] but the 
rate of removal is small when compared to the rate of admiuistration. Another 
example of a situation, which used to be managed by daily intense dialysis treannent, 
is kidney transplantation in a patient with primacy hyperoxaluria. In these patients 
plasma oxalate levels should be kept below 20 pmol/L [29] until the graft functions 
well. This is virtually impossible with intermittent treatment. However, with 
CA VHD, at a dialysate flow rate of approximately 4-5 L/hr, a constant plasma 
oxalate clearance rate of 40-50 ml/min can be achieved, which suffices to control 
hyperoxalemia. 
Logistic indications for treatment with CA VHD are especialiy justified if 
frequent dialysis treatment would interfere with other aspects of patient care and if 
the arterial blood access poses no particular problem. Frequent and prolonged 
investigations or operations can proceed without disconnecting the filter. 
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It has been hypothesized that continuous techniques can effectively remove 
inflammatory mediators associated with sepsis, the adult respiratory distress 
syndrome (ARDS) and multiple organ failure [30, 31]. This prompted Cosentino et 
a! to study the effect of CA VH in patients with ARDS, who had no renal failure. In 
this study, a beneficial effect on the course of ARDS could not be demonstrated [32]. 
It is likely, however, that, for most peptides, endogenous clearance rates are much 
faster than their removal by CA VH or CA VHD. Therefore, current research still 
focuses on tbe precise pathophysiological mechanisms involved in the multiple organ 
failure syndrome. The trend is to look for ways to more selectively remove or 
neutralize the key pathogenetic factors by affiulty columns or specific antibodies or 
drogs. 
CONTRAINDICATION$ FOR CA VHD 
If a patient has a vascular prothesis of the femoral artery located less than 20 em 
above the groin, the use of the femoral artery can be hazardous. Sometimes, due to 
extensive arteriosclerosis, canoulation of the femoral artery is impossible. In such 
cases, the axillary or brachial artety or, if blood pressure is high enough, a Scribner 
shunt may be used as an alternative vascular access. If none of these possibilities 
remains, then the use of pumped veno-venous hemodiafiltration should be considered. 
The main disadvantage of the pumped technique is that more specialized personnel 
are needed to watch this system. Moreover, if the pump is equipped with all the 
necessary alarms and safeguards, this implies that the pump can be interrupted which 
may lead to clotting of the system. 
In our view, CA VHD (or CVVHD) is contraindicated only if the extracmporeal 
circuit interferes with the mobilization of the patient. Thus, when a patient who has 
been treated with CA VHD, recovers, we tend to continue the treatment by 
intermittent hemodialysis. 
EQUIPMENT AND INSTRUCTIONS FOR USE 
A list of the necessary equipment for CA VHD is given below: 
1. Catheters for arterial and venous access (and the disposables used for their 
introduction). 
2. Small surface high-flux dialyzer. 
3. Arterial/venous blood tubing set with at least an entrance pon in the arterial 
blood line for heparin administration and preferably an additional arterial and/or 
venous pon for administration of substitution fluid. 
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4. illtrafiltration line. 
5. Graduated ultrafiltration collection bag or urometer. 
6. Heparin pump. 
7. Substitution pump, which can deliver up to 1000 ml!hr and infusion line. 
8. Dialysate pump, wllich can deliver up to approximately 5 L/hr, and 
corresponding infusion line. 
9. Weighing device. 
10. Dialysate heater. 
11. Heparin, substitution fluid and dialysate fluid. 
12. Two liters of rinsing fluid: NaCl 0.9%, containing heparin 5000 U/L. 
Priming and installation 
The purpose of priming a hemofilter is to eliminate air and, with some hemofilters, 
glycerine, wllich is used to prevent dehydration of the membrane. 
To prime the system, attach the blood lines and the ultrafiltrate line to the 
hemofilter. The ultrafiltrate outlet should be situated on the arterial site of the 
hemofilter to achieve a countercurrently dialysate flow. Place the hemofilter in a 
holder in the upright position, with the venous pon at the top. Connect the proximal 
end of the anerialline to the rinsing fluid bag and the distal end of the venous line 
to an empty sterile bag. Clatnp the ultrafiltrate line and run 1 to H~ liter of rinsing 
fluid through the blood lines and filter under gravity forces. Make sure that side pons 
have been rinsed as well and that all air has been eliminated. Then unclatnp the 
ultrafiltrate line and clamp the venous line. Run 'h liter of rinsing fluid through the 
system. In this way, forced ultrafiltration will occur and glycerine will be rinsed out 
of the pores of the membrane. Finally unclatnp the venous line and rinse the rest of 
the fluid through the system. 
After priming, the pumps, heater, urimeter, heparin, substitution fluid and 
dialysate fluid are connected to the system and the hemofilter, filled with rinsing 
fluid, is connected to the catheters. Figure 1 shows a schematic drawing of the 
hemofilter and the requirements. It is customary to position the filter with the 
ultrafiltrate/dialysate outlet up (not shown in the Figure), in order to ensure that any 
air in the dialysate companment leaves the companment immediately. The 
ultrafiltrate/dialysate container is positioned below the level of the filter in order to 
create a negative pressure in the dialysate companment and thereby enhaoce the rate 
of ultrafiltration. There must he no direct contact between the sterile dialysate exit 
pan and the container in which ultrafiltrate and dialysate are collected. The filter is 
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left in place as long as it functions well. If the ultrafiltration rate falls below 200 
ml/hr, and kinking of the catheters or blood lines has been excluded, the filter is 
replaced. When the patient must be transported, it is easiest to temporarily disconnect 
the dialysate infusion line and fix the filter onto the patient's leg. 
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Figure 1. Schematic drawing of CA VHD system 
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InCA VHD, blood flows spontaneously. Low blood flow rates may lead to excessive 
hemoconcentration and to early clorting of the filter. Therefore, high blood flow rates 
are desirable. Blood flow rate (Q •• [ml/min]) is a function of arterial and venous 
blood pressure and the total extracorporeal system resistance to flow: 
(l) 
where P~ and P,. [mmHg] are the pressures in the femoral artery and vein 
respectively and where R,. R,.. and R,. [mmHg • min/ml] are the resistances to flow 
of the filter, the arterial access and the venous access. Usually, the arterial and 
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venous access constitute approximately one half of the total resistance to blood flow. 
For straight catheters and for capillary hemofilters the resistance to flow is 
determioed largely by the intemal radius of the lumen as given by Poiseuille's law: 
(2) 
Here L is the length, N is the number of the capillaries, r is the radius of the catheter 
or capillary, and Jl is the viscosity of the medium [mmHg ·min]. 
The best results have been obtained with special shon wide bore CA VH-
catheters. Our experience is with L=ll.4 em catheters (M8CA VH4, Medcomp) with 
an internal diameter of 2.7 mm. With these catheters the average resistance to blood 
flow is 0.10 mmHg · min · ml"1 per catheter. Limited experience with 15 em 
'Shaldon catheters' (MCY306PS, Medcomp) with an internal diameter of 2.3 mm 
(8F) indicates an average resistance to flow of 0.16 mmHg · min • mr'. With 
Scribner shunts, the average resistance to flow was 0.36 mmHg ·min · ml"1, ie. 
3 to 4 times higher than with CA VH-catheters (see Chapter 4). It should be noted 
that the contribution to the total resistance to flow of the tubings from the catheters 
to the hemofilter need not be considered. With 180 em of tubing with an internal 
diameter of 4.36 mm, it can be calculated that the resistance to flow exened by the 
tubing alone is 0.07 mmHg · min · ml"1• Shonening of the tubing will have a 
negligible influence on the overall resistance to flow of the extracorporeal circuit 
With CA VH-catheters, blood flow rates are typically in the range of 100 to 250 
ml/min. Ideally, blood flow rate should be measured continuously. It is now 
technically feasible to measure blood flow rate by means of echo transit time 
measurement, using a flow probe around the blood line [33]. As an alternative, blood 
flow rate may be determined by injecting a 0.3 ml air bubble into the blood line and 
measuring the transit time of the air bubble over a known distance of the blood line 
[34, 35]. Calculation of blood flow from anerial and venous hematocrit and 
ultrafiltration rate is unreliable. 
CA VH-catheters are best placed in the femoral anery and vein. These vessels are 
usually wide enough to accommodate the catheters and the introduction procedure 
is simple. If the femoral vessels cannot be used, one may consider using the axillary 
or brachial anery and the jugular or subclavian vein for access. Scribner shunts may 
be placed in the lower leg or in the forearm. 
Reponed complications of anerial cannulation include dissection, thrombcsis, 
false aneurysm formation, fistula formation, infection, and superficial or 
retroperitoneal bleeding. Although this sounds alanning, Kramer et al have 
demonstrated that these complications were considerably reduced once specially 
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designed short catheters were used exclusively [36]. In recent series, with the use of 
special CA VH-cathetets, the incidence of damage to the femoral artery was reported 
to be 2% [37-39]. Furthermore, in a retrospective analysis, Swann et al found no 
evidence for either sepsis or increased morbidity related to catheter infections [ 40]. 
The hemofilter 
For CA VHD one needs a small surface highly permeable hemofilter with a low 
resistance to blood flow. Using a high surface hemofilter is not desirable. First, 
because it leads to an excessive ultrafiltrate production and thereby necessitates 
substitution infusion rates that are above the range of the intravenous infusion pumps 
that are generally available. Second, because a larger membrane surface area implies 
more extensive contact between blood and membrane material and, hence, a greater 
risk of clotting. High flux characteristics usually coincide with good biocompatibility 
[41]. For optimal function, a high diffusive permeability is also required. Protein 
adsorption to the membrane causes a decrease of membrane permeability over time. 
In view of the long duration of use, obviously, protein adsorption is undesirable. The 
typical hemofilter used for CA VH or CA VHD has short capillaries with a diameter 
of between 200 and 280 pm and a membrane surface area of between 0.2 and 0.6 m2• 
Knowledge of the resistance to flow is important, as in CA VH(D) blood flow 
is spontaneous generated by the pressure difference between the arterial and veoous 
access. Especially because it is no common practice to measure blood flow rate 
continuously, one should aim for a hemofilrer with a low resistance to flow to 
preveot early clotting and therapy failure. lf one uses a blood pump, the resistance 
to flow is of minor concem Table 1 provides manufacturer data of several filters for 
CA VH(D) that are available. From these data, the resistance to flow for capillary 
hemofiltets is calculated by using Poiseuille's law (Eq. 2). The resistance to flow for 
plare filtets is calculated according to: 
3·L·)l 
R, --;::-2-:· N~-m-:-'-;-· b'' (3) 
where N is the number of blood channels, m is the blood channel width and b is the 
blood channel half-height [42]. The viscosity used to calculate resistance to flow as 
giveo in Table l, is calculated as described by Pallone et al [43] and by using a 
correction factor (see Chapter 4), with a hematocrit of 0.30, a protein concentration 
of 50 mg/L and a temperature of blood of 36°C. When the resistance to flow is 
calculated from the manufacturer data, most of these have a resistance to flow below 
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0.30 mmHg · min/ml, which is suitable for CA VH(D). However, from in vivo as 
well as laboratory studies it is known that, very often, the actual resistance to flow 
is higher than the value that was calculated from the official specifications [44, 
Chapter 4]. Therefore, before a filter is used for CA VHD, one should best rely on 
precise determination of the resistance to flow in a laboratory setting [45]. The 
resistance to flow of a hemofilter has been found to be constant over time. Figure 2 
shows a recording of mean arterial pressure and blood flow rate within the CA VHD-
circuit over 5 days. Fluctuations in blood flow rate reflect those in mean arterial 
pressure (MAP, [mmHg]). Ouly after four days a precipitous drop in blood flow is 
seen. A few hours later the filter had become clotted completely. 
The ultrafiltration rate (Q,, [ml/min]) is determined by the hydraulic permeability 
of the membrane (4, [ml/mmHg ·min · m2]), the membrane surface area (S, [m2]) 
and the transmembrane pressure (TMP, [mmHg]): 
Q,=L,-S ·MP (4) 
or 
Q,=MI·TMP (5) 
where MI [ml/min • mmHg] is the more commouly used hydraulic permeability 
index of the membrane. A recording over time of ultrafiltration rate is shown in 
Figure 3. The data shown in Figures 2 and 3 were obtained from the same patient. 
It is apparent from Figure 3 that, while mean pressure and blood flow rate remained 
constant, ultrafiltration rate decreased over time. This indicates that MI and, 
presumably, Lp decreased over time. This phenomenon has also been demonstrated 
by others [46-48]. It has been shown that during continued use of a membrane, a 
decline in the hydraulic permeability occurs as a result of protein adhesion [49, 50]. 
We have described the average rate of decline of MI with three different hemofilters 
(Chapter 4). The data showed that the decline of MI was least apparent with a small 
polysulfone capillary hemofilter. The influence of hemofilter geometry and 
membrane material in this respect has not been studied in detail so far. 
InCA VH, high-flux membranes are used in order to obtain adequate convective 
clearance rates. In CA VHD, clearance occurs more by diffusion than by convection. 
The rate of ultrafiltration must still be high enough to be able to withdraw several 
liters of fluid per day. When using a high flux membrane, a total membrane surface 
area of 0.6 m2 is enough to obtain an ultrafiltration rate of 300 to 1000 ml/hr. 
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Both hydraulic and diffusive permeability have been found to decrease over time 
(Chapter 4, 6). Thus, a very low hydraulic permeability is associated with a low 
diffusive permeability. Generally, if clearance rates are inadequate, they may be 
effectively increased by increasing dialysate flow rate (Chapter 6). However, when 
membrane permeability has become poor, as reflected by an ultrafiltration rate of less 
than 200 ml/hr, the filter is best replaced. Changing of the filter can nearly always 
be postponed so as to take place during working hours. 
Table 1. Manufacturer data of CAVH(D) filters and calculated resistance to jltYW. 
Fres.= Fresenius, AN-69=Acrylonitrile-69, PS=Polysulfone, 
PA=Polyamide, P AN=Polyacrylonitrile. Jl = 3.5 ·10"7 mmHg ·min. 
1 
: Channel height, 2 : Channel length, 
' : Channel width, 4 :Number of blood channels, 5 : TMP = 55 mmHg, 
6
: Wet condition, 7 : Calculated from membrane surjae area. 
filter membrane membrane fiber fiber number effective R, calc 
wall diameter length of fibers membrane 
thickness pm em surface 
pm area. m2 
Hospal plate AN-69 23 200+ 26.8" 15' 0.43 0.11' 
0.26. 6.7' 
TMP' 
Hospal AN-69 506 2406 15 6000 0.60 0.11 
Mu!tiflow-60 
AmiconD-20 PS 75 250 12.7 5000 0.40 0.09 
AmiconD-30 PS 75 250 21.2 5000 0.70 0.15 
GambroFH 22 PA 60 215 14.1 2100 0.16 0.44 
Gambro FH 66 PA 60 215 17.2 6200 0.59 0.18 
Fres. A-V 400 PS 35 220 25.5 4500 0.70 0.34 
SorinHFT 02 PS 40 200 12.0 4600 0.24 0.23 
Rcnaflo HF250 PS 40 280 14.0 28007 0.25 0.11 
Rcnaflo HF500 PS 40 280 21.5 33507 0.50 0.15 
Asahi APF-03 PAN 35 250 18.5 3400 0.30 0.20 
Asahi APF-06 PAN 35 250 18.5 6400 0.60 0.11 
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Figure 2. Blood flow rate over time using the AN-69 capillary dialyzer (in vivo 
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Figure 3. Ultrafiltration flow rate over time using the AN-69 capillary dialyzer (in 
vivo data) 
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Fluids and jlqw rates 
In CA VHD, dialysate must be sterile in order to prevent back-transpon of products 
of pcssible contaminants, such as pyrogens, from dialysate to blood [51-53]. It is 
easiest to use a commercially available hemofiltration substitution fluid for dialysate. 
These fluids come in bags of up to 5 liters. In Table 2, several solutions are 
mentioned that can be used as dialysate fluid. Dialysate fluid for peritoneal dialysis 
is less suitable for use in CA VHD, mainly because of its low sodium content and 
high content of glucose. After a few days of treannent with CA VHD, at a dialysate 
flow rate of 1 L/hr, we frequently encountered hypckalemia, hypcphosphatemia and 
alkalosis. In our view therefore, the ideal dialysate solution should be compcsed so 
as to prevent electrolyte derangements during the stable phase of CA VHD treannent. 
At the stan of treatment, when serum potassium and phosphate are high and 
bicarbonate is low, the same dialysate fluid may srill be used albeit at a higher 
dialysate flow rate. We do not advocate the use of a range of different dialysate 
solutions, because it is impractical and because individual modifications or 
supplementations may still be needed. Therefore, it is recommended to measure 
serum levels of phosphate, potassium and sodium at least once a day. Until recently, 
all solutions contained either lactate or acetate as a buffer substitote, since the 
addition of bicarbonate would be precluded because of precipitation with calcium and 
magnesium. Presently, we use for dialysate a fluid to which bicarbonate is added just 
before use (Schiwa). When used within 24 hours, precipitation of calciumcarbonate 
is negligible. With bicarbonate containing fluids, the pcssible hannful effects of 
acetate and the inconvenience of spurious elevstion of blood lactate is eliminated. 
Furthermore, Jenkins et al have demonstrated that in children on CA VHD who have 
persistent metabolic acidosis, changing from lactate containing dialysate to 
bicarbonate containing dialysate considerably improves the metabolic acidosis [54]. 
Blood and dialysate run in oppcsite directions. This countercurrent flow 
increases the concentration gradient between blood and dialysate. In most cases a 
dialysate flow rate of 1 L/hr is enough to control the uremic state. The influence of 
dialysate flow rate on diffusion is extensively discussed in Chapter 6. 
As substitution fluid one may use simple Ringer's lactate. In case of 
hyponatremia, the addition of 1 gr NaCl to 500 ml of Ringer's lactate so as to 
increase its sodium concentration to 180 mmol/L, will lead to gradually correction 
of the hypcnatremia. Alternatively, if the patient is no longer acidotic, one might 
consider the use of isotouic saline for substitution fluid. Substitution can be given 
either by infusing the fluid on the arterial line (predilution) or on the venous line of 
the filter (postdilution). Predilution has several advantages [55, 56]. By predilution 
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the hematocrit and the plasma protein concentration are decreased, which leads to a 
decrease of the blood viscosity and an increase of blood flow rate. Also, at least 
theoretically, by lowering colloid osmotic pressure ultrafiltration rate will be 
increased. The flow rate of the substitution fluid must be adjusted hourly to the rate 
of ultrafiltration so as to achieve the desired fluid balance. It is recommended not to 
decrease the rate of ultrafiltration, as this would decrease clearance rates, especially 
of solutes with a high molecular weight. 
Table 2. Composition of fluids which can be used for dialysate fluid in CA VHD 
(mmoUL). 
Dialysa!e Na• K• ca'· Mg" cr Lact Ac· HCO; Glue 
Fres. HF11 140 1 1.63 0.75 101 45.0 0 0 10.9 
Fres. HF21 135 2 1.88 0.75 109 33.8 0 0 8.3 
Fres. HF02 140 0 2.00 1.00 111 0 35 0 0 
Scbiwa SH-44 HEP 140 2 1.75 0.50 112 2.9 0 31.4 5.6 
Scbiwa SH-35 HEP 140 0 1.75 0.50 110 2.9 0 31.4 5.6 
Scbiwa SH-36 HEP 140 4 1.75 0.50 114 2.9 0 39.7 5.6 
Scbiwa SH-41 HEP 141 0 0 0.72 108 0 0 34.3 5.6 
Hospal LO 140 0 1.75 0.75 100 45.0 0 0 0 
Hospal L2 142 2 2.00 0.75 110 40.0 0 0 0 
Hospal LG4D 140 4 2.00 0.75 110 40.0 0 0 6.1 
Gambro 140 1 1.60 0.75 100 45.0 0 0 11.1 
Hemofiltraso1 21 
Gambro 140 0 1.60 0.75 100 45.0 0 0 11.1 
Hemofiltrasol 22 
Gambro 140 I 1.80 0.75 100 45.0 0 0 11.1 
Hemofiltraso1 23 
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Pumps and weighing devices 
For safety reasons, we advise against the use of a pump in the blood line. If one 
were to use a pump in the blood line, this would at least necessitate the use of a 
bubble trap and monitoring of the pressures in the arterial blood line, intmediately 
after the pump (in order to detect clotting of the filter) and preferably also in the 
venous blood line. One migbt also argue that the extracorporeal system ougbt to be 
supervised by a renal nurse. 
For pumping dialysate fluid, a special pump that may deliver up to 3-5 L/br, is 
usefui but a simple screw clamp will also do. As dialysis fluid comes in big bags, 
it is necessary to use a weigbing device to check the amount of dialysate delivered 
evecy hour. The total amount of ultrafiltrate plus spent dialysate may be measured 
either by weigbing or by using a calibrated container. 
When substitution fluid is given into the arterial line ('predilution'), an infusion 
pump must be used because of the bigb pressure. In view of the bigb ultrafiltration 
flow rate that occurs in the first few hours, this pump must be able to deliver up to 
1000 ml/br. 
Anticoagulation 
Our practice is to stan with a heparin dose of 500 U/br, administered just before the 
hemofilter in the arterial line. No loading dose is given. The dose may be changed 
to between 250 and 750 U/br as clinicaliy indicared. In case platelets counts are 
below 20·109/L we give no heparin at ali. 
One ruigbt consider regional heparinization, i.e. heparin in the arterial line and 
protamine in the venous line [57]. Receotly, Mehta et al have published a scheme for 
citrate anticoaguiation in CA VHD [58, 59]. 
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DETERMINANTS OF BLOOD FLOW AND 
ULTRAFILTRATION: THEORETICAL PREDICTIONS AND 
LABORATORY AND CLINICAL OBSERVATIONS• 
INTRODUCTION 
Continuous arteriovenous hemofiltration (CA VH) and hemodiafiltration (CA VHD) 
are based on spontaneous blood flow and spontaneous ultrafiltration [1]. Failure of 
the technique may occur due to an inadequate blood flow rate, leading to excessive 
hemoooncentration and clotting. 
Theoretically, blood flow rate and ultrafiltration rate may be predicted on the 
basis of filter geometry, membrane characteristics and blood visoosity. Pallone and 
Petersen developed a malhemstical model by which they were able to predict filter 
perfonnanoe in a laboratory setting [2]. In their study the resistanoe to blood flow 
was in good agreement with model predictions. On the other hand, Olbricht et al in 
a clinical study found that the resistanoe to blood flow was 3 times higher than 
expected [3]. The aim of the present study was to examine the feasibility of 
predicting filter perfonnanoe under clinical oonditions. In patients who were treated 
with CA VHD we perfonned serial measurements of blood flow rate, blood pressures 
and ultrafiltration rate, so as to estimate the filter resistance to blood flow and its 
hydraulic penneability. We also measured filter resistanoe to flow in a laboratory 
setting. Clinical and laboratory data were then oompared with theoretical predictions. 
METHODS 
Clinical protocol 
Twenty patients were treated with CA VHD for acute renal failure and sepsis and/or 
circulatory or neurological instability. A hemofiltration substitution solution (HF-!1, 
Fresenius, Gennany) was used for dialysate. The CA VHD circuit was instailed as 
depicted in Figure 1 (for details, see Chapter 3). For vascular acoess we used special 
11 em CA VH-catheters (Medcomp, 8 F) in the femoral vessels, or Scribner shunts. 
Three types ofhemofilters were used (all specifications according to manufacturers): 
* Reprinted in revised fonn with permission from Nephrol Dial Transplant 1990,5: 1031-
1037 
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- the AN-69 plate fiher (15 compamnents, length 26.8 em, width 6.7 em, channel 
height 200+0.26 • TMP pm, membrane surface 0.43 m2; SCU/CA VHD, Hospal, 
France), 
- the AN-69 capillary filter (6000 fibers, length 15 em, including 2 em within 
petting, internal diameter of fibers 240 pm, and 220 pm within potting, membrane 
surface 0.6 m2; Multiflow-60, Hospal, France) 
- a pclysulfone capillary filter (4600 fibers, fiber length 85 em, internal diameter of 
fibers 200 pm, membrane surface 024 m2; Spiraflo HFT02, Solin Biomedica, Italy). 
d1alysat~ 
puO>p 
Figure 1. CAVHD system 
prcd!lvtion 
fluid 
container 
-T?N 
Filters were prepared by rinsing the blood compamnent with 2 L of saline, 
containing hepartn 5000 U/L, allowing filtration to take place (see Chapter 3 for 
rinsing procedure). Filters were placed in the upright position, with the ultrafiltrate 
outlet up. Ultrafiltrate column height was about 60 em. Standard anticoagulation 
consisted of hepalin 500 U/br into the arterial line of the filter. No loading dose of 
hepalin was given. No protamine was used. Tirree patients received no hepalin 
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because of excessive bleeding, thrombocytopenia or hepatic failure and coagulation 
disorders. Substitution fluid (Ringers lactate) was infused into the arterial line 
(predilution). The amount of substitution fluid was adjusted hourly to the net 
uitrafiltration (UF) rate. Reasons for filter replacement were clotting of the filter or 
a UF rate < 200 ml/br. Furthermore, filters were removed when dialysis was no 
longer necessary or when clinical improvement allowed mobilization of the patient, 
in which case patients were treated further with conventional intermittent 
hemodialysis. Thus, average filter 'survival' time was 3 days. 
In a separate study we took blood for viscosity measurements from 10 patients, 
aged 38 to 66 years, who had been treated in the intensive care department for at 
least three days. 
Laboratory protocol 
The 0.6 m2 AN-69 capillary hemofilter was studied in the laboratory. Filters were 
prepared by rinsing the blood compartment with 2 I of saline, containing heparin 
5000 U/L, allowing filtration to take place. After that, the dialysate compartment was 
closed. Blood tubing, with an inner diameter of 4.3 mm, containing side ports was 
used and adjuSted so we couid measure the pressure in the perfusion fluid 2 em 
before and after the hemofilter. An electromagnetic flow probe was inserted into the 
tubing so that mean flow rate could be measured continuously. 
The experiments were performed at room temperature. Filters were in the 
horizontal position. Eight filters were used. They were all first perfused with saline, 
then two filters were perfused with a sucrose solution and three filters were perfused 
with pig blood. A Rhodia!• blood pump was used to generate pulsatile flow rates 
from 50 to 600 ml/min in case of saline perfusion and from 50 to 300 ml/min in case 
of blood or sucrose perfusion. The filter resistance to flow was thus detennined at 
different flow rates. Furthermore, with all three solutions we once changed the set 
up so as to create an open circuit with a container at a variable height, in which a 
constant flow through the filter was generated by gravity and the pump was used to 
return the fluid to the container. 
We also measured the resistance to flow over 223 em of standard 
polyvinylc!J.!oride (PVC) blood tubing with an inner diameter of 4.36 mm, using 
saline as the perfusion fluid. 
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Measurements 
Electronic pressure transducers were connected to the anerial and the venous lines 
to measure the pre- and postfilter hydraulic pressures (P, and P, respectively). Both 
pressures were measured using the same pressure transducer. In the patients, we also 
measured intra-anerial and intra-venous (P~ and P,v) pressures by the same pressure 
transducers after clamping the line for l 0 seconds. The pressure midway in the 
ulttafiltrate-companment (P,, [mmHg]) was calculated from the height of the flnid 
column in the UF-line (h, [em]) according to: 
h P=-
' 1.36 
(1) 
where the value 1.36 is needed for the conversion from cmH,.O to mmHg. Effective 
transmembrane pressure (TMP) in the filter was calculated according to: 
P.+P, 
TMP=-'- -P, -COP 
2 
(2) 
where COP [mmHg] is the colloid osmotic pressure caused by the protein in the 
blood companmenL (Bemouilli effectS were thus neglected, see Discussion). Colloid 
osmotic pressure was calculated according to the equation of Landis and 
Pappenheimer: 
COP= 2.1 ·C"', + 0.16 · C""2 + 0.009 • C,.,' (3) 
where C"', is the mean plasma protein concentration (g/dl) in the filter. This equation 
had previously been found to fit experimental data closely over the range 0 to 25 % 
of protein [4]. When we compared measured and calculated values, the difference 
was always less than 5 mmHg (n=l2). 
cpro, is calculated according to: 
(4) 
where cpro,~ and cpro,.v are the plasma protein concentrations at the filter inlet and 
outlet respectively; QP" [ml/lllin] is the plasma flow rate through the anerial catheter 
before addition of predllution flnid, which is calculated as: 
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Q,. = Q, ·(1 -Ht) (5) 
where Ht is the blood hematocrit, Q""" is the predilution fluid infusion rate; Q, the 
ultrafiltration flow rate and Ht the hematocrit. In the patients, blood flow through the 
filter was determined in duplicate by measuring the time required for air bubble 
displacement over 13.0 ml of tubing. In the laboratory blood flow was measured with 
an electromagnetic flow probe (see laboratory protocol). Ultrafiltration rate was 
determined by timed collection of fluid from the ultrafiltrate line over five minutes 
after switching off the dialysate pump. Filter membrane index (MI, [ml/h • mmHg]) 
was defined as: 
Q ·60 
MI=-'-TMP 
(6) 
Hydraulic membrane permeability of the membrane (L•, [em/min • mmHg]) was 
calcuiated from: 
L =-MI-= Q, 
• S TMP·S 
(7) 
where S [ cm2] is the membrane surface area of the filter. 
The resistance of the filters to blood flow [R, mmHg · min/mll was calculated 
according to: 
P. -P 
R,=-' -' Q, (8) 
and resistances of the arterial and venous access were likewise derived from the 
pressure dtop P"' • P1 and P, - P,v respectively. Resistances were normalized for blood 
viscosity according to: 
(9) 
where, for blood, viscosity (p., [mmHg ·min]) is calcuiated as described by Pallone 
et al [5], assuming a blood temperature of 37 'C in the patient for calcuiating the 
resistance of the arterial access and of 34 'C in the filter for calculating the resistance 
of the filter and the venous access and taking the effect of ultrafiltration on 
hematocrit and protein concentration into account. In narrow tubes blood viscosity 
may be decreased according to the Fabreus Lindqvist effect. With a diameter of 200 
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to 240 Jllll, however, the decrease is less than 5 % and may therefore be neglected 
[6]. Values of viscosity for the salioe and sucrose solutions were taken from 
published tables [7]. 
Under the conditions of our study, with shear rates of 150 to 400 sec·', blood may 
be regarded as a Newtonian flnid [8]. Furthermore, within the fibers, blood flow is 
laminar. Therefore, R, may also be predicted according to Poiseuille's Law: 
(10) 
where L is the fiber length; N is the number of fibers and r is the internal radius of 
the fibers of the hemofilter. 
For the flat plate filter, R., was predicted according to: 
(11) 
where N is the number of blood channels; oo is the blood channel width and b is the 
blood channel half-height [9]. 
Viscosity measurements were performed using an apparatus that measures the 
flow rate of blood at 37 oc through a glass capillary with a known resistance. The 
internal diameter of the capillary is 1.05 mm and the velocity is approximately 30 
mm/sec, resulting in shear rates similar to those within the fibers of the hemofilters. 
Statistics 
The clinical data are presented as means± I S.D. The time dependent decrease of 
hydraulic membrane permeability was analyzed by regression analysis. Previous 
experiments showed that a good fit was obtained by linear regression of the filter 
membrane index or hydraulic membrane permeability as a function of the logarithm 
of time (Ln t). This regression analysis was performed for each individual filter. An 
approximately equal number of data points were obtained before and after 12 h of 
use (for number of data, see Table 4). Slopes and extrapolated values at 12 h of use 
were compared by Wilcoxon's Rank test 
Filter resistance, measured in the laboratoty, was plotted against flow rate and 
linear regression analyses were used to calculate the resistance at zero flow rate and 
to determine the slopes. 
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RESULTS 
Blood path resistance and blood fi(JW rate 
On starling CA VHD treatment, mean arterial pressure was below 70 mmHg in a third 
of the patients. The CA VH-catheters bad a resistance to blood flow of only 0.10 
mmHg per ml/min, while for the Scribner shunt this value was fourfold bigber (Table 
1). The average filter resistance to blood flow was between 0.24 and 0.35 mmHg per 
ml/min. Generally, there was no appreciable change in filter resistance with lime. ln 
a few cases, a sudden increase in the resistance to blood flow heralded clotting of the 
filter. Using CA VH-catheters, overall blood path resistance during CA VHD treatment 
was approximately 0.45 to 055 mmHg per ml/min. This resulted in blood flow rates 
of 164 ±59 ml/min (range 63-284 ml/min). 
The normalised resistance, R,, of the hemofilters we observed was two to three 
limes bigber thao the predicted value (Table 1). This was partly explsined by 
underestimation of blood viscosity. Blood viscosity proved to be 1.4 limes bigber 
than the value calculated according to Pallone et al [5] (Table 2). 
Results of laboratory expeliments are given in Table 3 and Figures 2 and 3. For 
the PVC tube, the resistance to flow was in accordance with that predicted according 
to Poiseuille's law. For the hemofilter, both with saline and with the sucrose solution, 
the resistance was 40 % bigber than the calculated value. Similar values were 
obtained with either pulsatile or constant flows. The resistance rose with increasing 
flow rate. With blood, the resistance to flow was 160 % bigber thao the calculated 
value, and it did not significantly increase with flow rate. 
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Table 1. Resistance to blood flow (clinical data). PS= polysulfone 
R,- [mmHg • mill/mil Rrn [!o'!ml] n 
CA VHD catheter art 0.!0 ± 0.04 3.8 ± 1.3 39 
ven 0.!0 ± 0.04 3.7 ± 1.3 39 
Scribner shunt art 0.36 ± 0.07 14.8 ± 3.! 6 
ven 0.36 ± 0.!3 14.7 ± 5.4 6 
AN-69 plate filter: 
calculated 3.0 ± 0.2 
observed 0.25 ± 0.06 8.8 ± 2.2 16 
AN-69 cap. filter: 
calculated 3.0 
observed 0.24 ± 0.!1 9.0 ±4.0 17 
PS cap. fllter: 
calculated 4.7 
observed 0.35 ± 0.14 !1.4 ± 2.3 17 
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Table 2. Whole Blood Viscosity Measurements. 1 See ref [5] 
No. Ht c,... )l obslpred' 
10"7 mmHg • min 
1 21 55 2.84 1.33 
2 31 49 3.55 1.49 
3 25 55 2.66 1.17 
4 21 53 3.23 1.54 
5 26 36 3.06 1.53 
6 33 45 3.69 1.55 
7 30 75 3.93 1.41 
8 34 54 3.96 1.54 
9 26 54 3.05 1.33 
10 24 56 3.11 1.38 
mean± SD: 3.31 ± 0.43 1.43 ± 0.12 
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Table 3. Resistance w Blood F/(JW (Laboratory Data) 
BLOOD TUBING 
saline 
]1=1.2·10"7 
HEMOFJLTER 
saline 
]1=1.2·10"7 
HEMOFJLTER 
sucrose 
]1=2.8•10"7 
HEMOFJLTER 
Pig blood 
Ht= 0.23-0.26 
)1=2.8·!0·' 
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R., predicted 
IO'mr' 
2.41 
3.24 
mean± SD: 
3.24 
mean± SD: 
3.24 
mean± SD: 
R., measured 
IO'mr' 
2.15 
4.58 
5.17 
5.83 
2.92 
5.00 
4.69 
3.88 
4.60 
4.58 ± 0.82 
5.43 
3.98 
4.71 ±0.72 
7.93 
8.11 
8.93 
8.33 ±0.44 
Slope% per 
100 ml/min 
0.00 
8.8 
8.8 
6.0 
10.0 
8.1 
4.1 
6.0 
6.1 
7.2 ± 1.8 
5.1 
4.9 
5.0 ± 0.1 
1.5 
-0.4 
0.5 
0.5 ± 0.8 
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Resistance mmHg min I ml 
0 , I 
+ ++++ 
+ +++++ ++ + 0.081 + -+ 
+- +..,.. ++++ +++ 
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I 
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I - -
0.02 r TUBING SALINE ---
oL------L-----~----------~------~----~ 
0 100 200 300 400 500 600 
Flow ml I min 
Figu;re 2. Resistance to fWw of tubing and of AN-69 capillary filter, using saline. 
(Eypredicted tubing= 0.03, R1predictedfilter = 0.04). 
Resistance mmHg min I ml 
0.3,-----------~--------------------------, 
0
·
25 FILTER BLOOD 
t++-l::r.ry_+-11- ++++++++ ++ ++ + + + 
0.2 
FILTER SUCROSE 
0.15 
0.1L-----~----~-------------L------L-----~ 
0 50 100 150 200 250 300 
Flow ml I min 
Figu;re 3. Resistance to fWw of AN-69 capillary filter, using sucrose and blood. 
(Ey predicted = 0.09). 
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Table 4: Hydraulic membrane permeability. The average L,-values of2.77 and258 
for the AN-69 filters were both lower than the value of 5.03 for the 
polysulfone filter (p<O.Ol) The slopes 0.72 and 0.69 for the capillary 
filters were both lower than the slope of 135 for the plate filter (p<0.05). 
IJ Value obtained by interpoltalon 
21 Slope b in the formula L, = a - b In( time) 
AN-69 capillary AN-69 plate PS capillary 
L,' after 12 br slope' L,' after 12 br slope' L,' after 12 br slope• 
2.69 0.39 2.81 0.67 6.47 0.55 
3.66 !.55 0.56 1.62 5.94 !.30 
2.57 0.60 5.70 1.79 4.11 0.05 
2.14 0.34 2.34 0.84 6.27 0.70 
2.90 0.73 2.26 1.05 4.50 1.27 
2.60 0.98 2.87 2.01 6.53 0.53 
2.81 0.87 2.02 1.53 
2.97 1.26 
3.35 1.05 
2.85 1.10 
3.23 1.08 
0.92 1.03 
1.71 2.53 
average: 2.77 0.72 2.58 1.35 5.03 0.69 
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Figure 4. Decrease of filter membrane index with time. 
AN-69 0. 4 m' AN-69 0.6 m' 
plate filter capi ll. fi Iter 
Qb 250 
ml/min 
200 
"0 
"0 
Qf 1-000 
mJ!hr 
800 y 
600 
___::----
.ao 
-------
"h 
"h 200 
60 80 100 120 60 80 1 00 120 
MAP mmHg MAP mmHg 
'" " TIME h<>urs 
Polysul(one: 0. 2m1 
cap ill. filter 
/ 
~ 
60 80 "0 no 
MAP mmHg 
Figure 5. Estimated average extracorporeal blt:iodflow and ultrafiltration rate as a 
junction of mean arterial pressure. 
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Hydraulic membrane permeability 
Hydraulic membrane penneability of the AN-69 membrane was less than that of the 
polysulfone membrane (Table 4). This difference was largely made up for by the 
difference in membrane surface area of the hemofilters. Hydraulic membrane 
penneability decreased with time. The rate of the decrease was faster with the plate 
filter than with the capillary filters (see also Figures 4 and 5). 
DISCUSSION 
Blood flow 
Pallone and Petersen have shown that, for capillary and flat plate hemofilters, the 
resistance to flow may be predicted from the filter geometty [2, 5]. Their prediction 
was based on Poiseuille's law. In their calculations it was assumed that blood 
behaves as a Newtonian fluid and that flow through the filter is lamina!. In addition, 
they used data from the literature which allow the calculation of blood viscosity from 
hematocrit, protein concentration and temperature. In our study we used the same 
calculation methods. We found that the filter resistance to flow was two to three 
times higher than the predicted value. A similar finding has recently been reported 
for a number of other hemofilters [3]. To explain this discrepancy we considered 
clotting of fibers, underestimation of blood viscosity, turbulent flow and/or additional 
pressure losses due to the sudden changes in the blood path diameter and deviations 
of the internal diameter of the fibers. 
Laboratory measurements showed that the resistance of a length of tubing was 
in accordance with the calculated value, which argues against gross methodological 
mistakes. The resistance of the hemofilter, perfused with saline or a sucrose solution, 
was 40 % higher than expected. Furthennore, it was to some extent flow dependent, 
suggesting that turbulence does occur, most likely at the filter inlet. However, this 
can hardly explain why the extrapolated resistance at zero flow rate was 40 % higher 
than calculated. Also, when we applied Bemouilli 'slaw to estimate the pressure drop 
that results from the sudden change in diameter at the filter inlet [7], we calculated 
a pressure drop of far less than 1 mmHg. On the other hand, a 40 % increase in 
resistance would be explained if the fiber diameter would be a mere 8 % lower than 
the given value. When filters were perfused with blood, the viscosity-corrected filter 
resistance was higher than with saline or sucrose. With blood, a similar filter 
resistance was found both in laboratory expetiments, where clotting was prevented 
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by a high dose of heparin, and in the clinic. This argues against a significant 
contribution of clotting of fibers to filter resistance. Furthermore, in Chapter 3 it was 
observed that filter resistance was constant over time. On the other hand, comparison 
of actual blood viscosity with the calculated value confirmed our suspicion that we 
bad grossly underestimated blood viscosity. With blood, filter resistance no longer 
seemed flow dependent, probably indicating that turbulence is diminished by the 
higher viscosity of blood. If blood flow rate was prediCted on the basis of our 
laboratoty data on filter resistance during saline perfusion and on the basis of a more 
accurate estimation of blood viscosity, flow rate would be overestimated by only 
25%. 
Ultrafiltration 
The fall in ultrafiltration rate with time may be explained both by cbanges in the 
hydraulic membrane penneability, presumably resulting from protein adsorption to 
the membrane, and by a fall in the available membrane surface area, e.g. due to 
inadvertent clotting of fibers. For reasons given above, under clinical conditions 
inadvertent clotting of fibers is unlikely to occur. Therefore, the decrease in hydraulic 
membrane permeability with time is more likely to be due to ongoing protein 
adsorption. It should be noted that according to Jenkins et al [10] the hemofilter 
hydraulic membrane penneability may fall even after contact with water alone. To 
our knowledge, however, this finding has not been reproduced by others. For the 
AN-69 capillary filter we did not observe a fall in hydraulic membrane permeability 
between 1 and 48 hours of saline perfusion, but we do observe a fall in hydraulic 
membrane penneability with plasma and blood (data not shown). 
Clinical Implications 
In critically ill patients, in whom CA VH(D) is indicated, blood pressure tends to be 
low. A low resistance to flow of the extracorporeal circuit is therefore mandatoty. In 
this respect CA VH catheters are clearly to be preferred to Scribner shunts. The use 
of a Scribner shunt instead of catheters doubled the overall resistance of the 
extracorporeal system. In our view Scribner shunts should be regarded as unsuitable 
for CA VH(D). 
The resistance to flow of the hemofilters studied was low enough to ensure an 
adequate blood flow rate in most cases. By using laboratory data on filter resistance 
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and a more accurate estimation of blood viscosity, a reasonably accurate prediction 
of blood flow rate under clinical conditions can be obtained. 
With the three filters Sllldied, ultrafiltration rate is always high enough for 
correction of overb.ydration. On the other hand, due to the time-dependent fall in 
hydraulic membrane permeability, ultrafiltration rate will soon become too low for 
adequate solute removal through convection alone. In case of CA VH this necessitates 
frequent changes of the filter. In case of CA VHD the fall in filtration rate is less 
important, as solute removal then occurs largely by diffusion. 
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A MATHEMATICAL MODEL OF SOLUTE TRANSPORT IN 
CONTINUOUSARTEIDOVENOUSHEMOD~TRATION 
~TRODUCTION 
Continuous arteriovenous hemofiltration (CA VH) is characterized by the use of a 
small surface highly permeable hemofilter, spontaneous blood flow and spontaneous 
ultrafiltration. Solutes are removed solely by convection, i.e. plasma water is 
removed together with all dissolved molecules that are able to pass through the 
membrane pores. The driving force is the trans membrane pressure difference. Solute 
clearance is limited by the amount of ultrafiltrate produced. It is techulcally feasible 
to increase ultrafiltration rate by the use of a pump, either in the blood circult or in 
the filtrate line, but the inherent hazards of such techulques necessitate the use of 
sophisticated safety measures and supervision by specially trained personnel. An 
easier way to increase solute clearance is by continuous arteriovenous 
hemodiafiltration (CA VHD), a techulque in which CA VH is combined with 
continuous slow dialysis [1, 2]. In this techulque, transpon occurs by combined 
convection and diffusion. Both processes have an influence on one another [3]. 
Ultrafiltration leads to an increased solute concentration in the dialysate side of the 
dialyzer and thereby decreases diffusion. Dialysis lowers the solute concentration in 
plasma water and thereby decreases the amount of solute that is removed by 
ultrafiltration. 
CA VHD is a new renal replacement techulque. Insight into the determinants of 
solute clearance is needed to determine the optimal flow rates. Also, data on drug 
clearance are needed. For some drugs dose adaptations may be necessary. For this, 
we needed a mathematical model that could be used to analyze solute tnmspon by 
CA VHD. We must realize that CA VHD differs from conventional intermittent 
hemodialysis and hemodiafiltration in several respects. First, solute transpon occurs 
by simultaneous convection and diffusion. Second, dialysate flow rates (10-30 
ml/min) are very low compared to blood flow rate (100-250 ml/min) and as a 
consequence the change in dialysate solute concentration over the length of the filter 
cannot be taken to be linear, as in conventional models of dialysis [4]. The dialysate 
flow rates that are used in CA VHD might be too low for optimal distribution of 
dialysate over the dialysate compartment. Consequently, by low dialysate flow rates, 
the resistance to diffusion exened by the dialysate compartment may be much higher 
than in conventional hemodialysis. Third, CA VHD is a continuous techulque. With 
prolonged use of the filter, deterioration of the membrane is likely not ouly to 
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decrease the rate of ultrafiltration but also to impair diffusive transport. For the above 
reasons, existing models of hemodialysis are not likely to be useful for the analysis 
of solute transport. in CA VHD. 
Previous models of solute transpon by hemodiolysis 
In the model of hemodialysis, as published by Sargent and Gotch [4], a linear change 
in solute concentration over the length of the dialyzer is assumed. Convective 
transport. is neglected. Thus the rate of transport depends on the difference between 
the concentration in blood and that in dialysate and the mass transfer coefficient of 
diffusion (KJ. By using this model, the length-averaged K. may be calculated from 
the total solute transport. and the log-mean concentration difference over the 
membrane [4]. In CA VHD, the contribution of convective transport is relatively 
great. Also, because of the ratio of blood and dialysate flow rates, a curvilinear 
decrease of solute concentration over the length of the dialyzer is to be expected. 
The mass transfer coefficient of diffusion is the inverse of the total resistance to 
diffusion, which consists of the resistance to diffusion of the blood compartment, that 
of the membrane and that of the dialysate compartment [5]. In conventional dialysis 
the greater pan of the resistance to diffusion is exened by the blood compattment 
and the membrane. According to Grimsrud and Babb [6], at a fast and turbulent 
dialysate flow, the resistance to diffusion in the dialysate compattment approaches 
zero. Accordingly, they developed a model of solute transpon in which the resistance 
to diffusion of the dialysate compattment was neglected. Also, in their model 
ultrafiltration rate was taken to be zero. In CA VHD, this approach is not valid 
because of the low dialysate flow rate and the relatively high rate of ultrafiltration. 
Sigler and Teehan first described solute clearance by CA VHD in patients [7]. 
They did not discern between convective and diffusive clearance and the study does 
not provide any insight into the determinants of diffusive transport. 
Pallone et al studied solute transport by CA VHD in a laboratory sening. They 
presented a model in which they defined the solute flux by convection and by 
diffusion. These fluxes were then integrated over the length of the dialyzer [8]. With 
their model, they were able to calculate the curvilinear change in solute concentration 
along the dialyzer. Their model does not provide an analytical expression ofK.. They 
did not recognize the influence of differences in dialysate flow rate on K. (Chapter 
6). 
J affrin published a mathematical model of combined convection and diffusion, 
to be applied to intermittent hemodiafiltration [9]. He expressed K. as a function of 
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the resistance of diffusion in blood, in the membrane and in dialysate. These values 
are, however, not readily available. Furthermore, in order to derive K,, experiments 
had to be done at zero ultrafiltration rate. The model can therefore not be applied to 
data obtained from patients treated with CA VHD. 
In view of the shortcomings of the above models, we developed a new model 
of CA VHD. In the present chapter, we first define a model ofhemodiafiltration that 
can be easily implemented in any spread sheet program. Then, with some 
simplifications, the model equations are analytically solved, so as to provide an 
expression of K, as a function of blood, filtrate and dialysate flow rates and solute 
concentrations. By virme of this expression of K,, the model is well suited for the 
analysis of diffusive transport in CA VHD. 
MathematicalrMdel of CA VHD 
The model describes the flux of a solute from plasma water to dialysate by 
simultaneous convection and diffusion during countercurrent hemodiafiltration. The 
solute concentration at the dialysate inlet is taken to be zero. 
Three important assumptions are made. Frrst, blood and dialysate flows are 
assumed to be homogeneously distributed over their respective compartments. 
Second, the membrane penneabilities for ultrafiltration and for diffusion are assumed 
to be constant over the entire membrane length. Third, within both the blood and 
dialysate compartments, the solute concentration varies in the axial direction but not 
in the radial direction, i.e. calculations are based on local "mixing cup" 
concentrations. In reality, the so called 'concentration polarisation' occurs on both 
sides of the membrane. Thus, in our model, diffusive solute transport results from 
a difference between mixed concentrations in plasma water and dialysate only. The 
influence of solute concentration polarization on the resistance to diffusion is thereby 
neglected. The validity of the latter assumption was experimentally studied (see next 
chapter). 
Input variables of the model are: 
blood flow rate at the inlet of the dialyzer (Q,), 
hematocrit (Ht), 
plasma protein concentration (C""J, 
dialysate flow rate (Q.), 
ultrafiltration rate (Q,), 
infusion rate of predilution fluid (Q,J, 
solute concentration in the arterial blood plasma (c;,), 
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total membrane surface area (S), 
the length of the membrane (L) and 
the mass transfer coefficient of diffusion (K,). 
Also the non-protein-bound fraction of the solute (F) and the sieving coefficient (s) 
are required. The sieving coefficient is the fraction of the solute mass that passes 
througb the membrane during ultrafiltration, defined as the solute concentration in 
ultrafiltrate divided by its concentration in plasma water. From these input values, 
we calculate the changes in solute concentration in blood and dialysate over the 
length of the dialyzer and, thereby, solute clearance. 
Model equations 
The flow rate of plasma water at the blood inlet (Qw;) is calculated by: 
Qw; = Qb, ·(I- Ht) ·(1- a ·C,.,) + Qb, • Ht ·f + Q""" (1) 
where f is the fractional solute distribution in red blood cells. For urea f is 0.8 [10]. 
For most other solutes f may be taken to be zero. C,., is the plasma protein 
concentration in giL and a, the volume fraction of proteins, is 0.00107 L/g [11]. The 
solute concentration in plasma water at the inlet of the dialyzer (C..J is calculated by: 
c . - cp, . c~ - Q""") (2) 
~ (I 0t ·C.,.,) Qwi 
The plasma water flow rate at the blood outlet CQwol is calculated by: 
~=~-~ ~ 
and the dialysate flow rate at the dialysate side outlet (Q.,J is: 
Q., =Q, +Q, (4) 
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The trans membrane pressure difference is the sum of the hydraulic pressure in blood 
and dialysate (P, and P, respectively) and the colloid osmotic pressure in blood 
(COP): 
(5) 
The value of COP may be estimated from the blood protein concentration by using 
the Landis-Pappenhelmer equation [12]. The hydraulic permeability coefficient of the 
membrane (Lp) is calculated from the rate of ultrafiltration, the length-averaged trans 
membrane pressure difference (TMP) and the membrane surface area according to: 
L - Q, 
' TMP·S 
(6) 
The volume flux (J,=Q, I S) is a function of the trans membrane pressure difference 
(TMP) and the hydraulic permeability: 
J =TMP·L 
• p 
(7) 
Solute flux through the membrane (J.) occurs by convection and diffusion. The most 
rigorous expression of J, during combined convection and diffusion is: 
H.·~ 
J ·s·[C -C ·e '] J = v w d 
' ' (-1.·-,2 
l -e · 
(8) 
This equation is equivalent with the one derived by Levitt [13]. In case of high 
values of J, · s and low values of K,, the above equation reduces to: 
J ·s 
for -'->>1 
K, 
(9) 
In case of low values of J, · s relative to the value of K,, eqoation 8 reduces to: 
Cw+C, J =J ·s· +K ·(C -C) $ v 2 d w d 
J ·s 
for -'-<<1 K, 
(10) 
In case of uremic solutes, protein-binding does not usually occur. With drugs, on the 
other hand, very often pan of the solute is bound to plasma proteins and ouly the 
free fraction (F) is avallable for convection and diffusion. To take the effect of 
protein binding into account, in Eq. 9 and 10 the value of C,. must be substituted by 
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A B c D E F G H 
I x/L Qw Qd Mw Md Cw Cd Js 
2 0.00 Qwi Qdo Qwi·Cwi Qdo.Cdo D2/B2 E2/C2 Jv·F2·P+Kd·(F2·P·G2) 
3 0.01 Qwi-0.01·Qf Qdo-0.01-Qf D2-0.01•S•H2 E2·0.o! •S•H2 D3/B3 E3/C3 Jv•FJ•P+Kd{FJ•P-GJ) 
4 0.02 Qwi·0.02-Qf Qdo-0.02-Qf D3 .0.01·S·H3 EJ-0,01 ·S·H3 D4/B4 E4/C4 Jv•F4·P+Kd{F4·P-G4) 
L__ --
' 
--
--- ------ --· -· 
101 0.99 Qwi-0.99-Qf Qdo-0.99·Qf DJ00.0.01·S·HJOO EJ00·0.01·S·HJOO DJOl/BJOJ ElOl/ClOJ Jv·FJOJ•F+Kd{FJOJ•F-GJOJ) 
102 1.00 Qwo Qdi DJ01-0.01•S•HJOJ El01-0.01•S•HJOJ DJ02/BJ02 El02/Cl02 Jv·Fl02·F+Kd{FJ02·F-GJ02) 
~ ------·-···"-- .__ - ---
-
Figure I. Stepwise numerical integration in a spreadsheet program. Note that, an approximation procedure must be used to find the value 
of C.., at which the value of cell GJ02 approaches zero. 
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C, · F. This implies immediate re-equilibration between bound and free fractions 
as solute is removed from the blood. Thus, Eq. 9 becomes: 
and Eq. 10 becomes: 
J •S 
for _v_>>l 
K, 
J ·s 
for -v-<<1 
K, 
(ll) 
(12) 
For the calculation of total solute transport, Eq. 11 or Eq. 12 is integrated along the 
length of the dialyzer. 
Implementatibn of the model in a spread sheet program 
The above model is implemented in a spread sbeet program as follows (see Figure 
1). 
The length of the dialyzer is divided into sections. At each section, d(x), Pb(x) is 
defined as a linear function ofP" and P .. ; TMP(x) is defined as a function ofPb(x), 
P, and COP. Since, in CA VHD, the ultrafiltration rate is small in relation to blood 
flow rate, one may use a single length-averaged value of the blood protein 
concentration and of COP. Also, at a low dialysate flow rate one may use a single 
value of P,. Jv(x) is then defined as a function of TMP(x). Q,.(x) and Q,(x) are 
expressed as a function of Qw; and Jv(x) and of Q,. and Jv(x) respectively. The total 
solute mass in plasma water, Mw(x), is defined as a function of MW,, which is the 
product of Qw; and Cw;. and J,(x). Likewise the total solute mass in dialysate is 
defined as a function of MW. and J,(x). Thus, to start the procedure, an estimated 
value of c,. is required (see below). C,.(x) and C.(x) are defined as a function of 
mass and flow rate. Fmally, at each section, J, is defined according to Eq. 11 or 12. 
An iterative approximation procedure is used to find the input value of c .. at which 
cdl becomes zero. 
If c ... is known and K, must be determined, then an initial estimation of K, is 
required and the approximation procedure is followed to find the value of K, at 
which cdl becomes zero. 
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Simplification of the model and analytical solutions 
In the case that the free fraction, F, and the sieving coefficient, s, of the solute equal 
one, as is true for urea, creatinine and phosphate, the transpon equation (Eq. 11) 
becomes: 
J ·s 
for -v->>1 (13) 
K• 
If, for simplicity, we assume that Jv is constant along the length of the filter, it is 
possible to obtaio an analytical expression of C,.(x) and C.(x) as follows [14, 15]: 
From the condition of continuity over a differential length d(x) of the hemofilter it 
follows that: 
dQw(x) dQ.(x) 
--=---=-w·J dx dx v 
where w is the width, defined as S/L. Iotegtation of Eq. 14 yields: 
Qw(x) =Q... -w ·Jv ·x 
and 
Q.(x) = W • Jv ·X - Q., 
Mass transfer of the solute io the blood compartment is given by: 
d[~(x) ·Cw(x)] _ -w ·J (x) 
dx ' 
and io the dialysate compartment by: 
d[ Q.(x) • C.(x)] 
w ·J,(x) 
dx 
where the solute flux is: 
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(18) 
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By combining Eqs. 14, 17 and 18 we get: 
and 
dC/x) K• · (Cw(x) - c.(x)) 
--~--=-W----~Q~w(~~~--
dC.(x) CJ. + K.) · (Cw(x) - C.(x)) 
--~-- = w -------.,Q.;<..,-(x") -----
(20) 
(21) 
On substracting Eq. 21 from Eq. 20 and eliminating d(x) by Eq. 14 we obtltin: 
do C(x) n dQw(x) - (n + 1) dQ.(x) (22) 
oC(x) Qw(x) Q.(x) 
where n = KJJ~ Integration of Eq. 22 along the length of the filter yields: 
(C)x) - C.(x)) = [Qw(x)]" "[-Q.(x)r<',.'l ·( -Al) (23) 
where A 1 is an integration constant The condition of conseiVation of solute, both 
in blood and dialysate side, implies: 
Q/x) ·Cw(x) + Q.(x) ·C.(x) = A2 (24) 
where A2 is a constant Multiplying Eq. 23 by Qw(x) we find 
Qw(x) ·(Cw(x) - C.(x)) = -AI [Qw(x)]"•' · [ -Q.(x)r<n·ll (25) 
and multiplying Eq. 23 by Q.(x) we find: 
Q.(x) · (Cw(x) - c.(x)) = Al [Qw(x)]" · [ -Q.(x)r" (26) 
Substracting Eq. 25 from Eq. 24 and adding Eq. 26 to Eq. 24 we find: 
c (x) = 1 A2 + A1 [Q (x)r' +n (x)J-<n•'l (27) 
d ~-Q., w ..... 
and 
C (x) = 1 A2 + A1 [n (x)]" +" (xW" (28) 
w ~Q., '<w ..... 
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From the boundary conditions at x = 0 we find: 
AI= (C"- Cwi)(Q .. r' ·(Q..)-n (29) 
and 
A2=" ·C -" ·C 
"wi. wi "<do do 
(30) 
Substitution of AI and A2 in Eqs. 27 and 28 and their further elaboration gives the 
concentration profile on the dialysate side: 
and the concentration profile at the blood side by: 
Because of the boundary condition C'" = 0, Eq. 31 gives us an expression for the 
ratio of the diffusive mass transfer coefficient to the volume flux: 
1 (33) 
When membrane total surface area, flow rates and solute concentrations are known, 
Eq. 33 may be used to calculate the value of n and of K,. By substituting the value 
of n in Eqs. 31 and 32 one may calculate the solute concentration profiles. 
Alternatively, for the case that both the sieving coefficient of the solute and the free 
fraction equal one. Convective solute flux may also be regarded as the volume flux 
times the solute concentration in the membrane (C,) approximated by (C, + C;J/2, 
rather than that in plasma water (C,J. Now startiog from Eq. 12, by substituting Eq. 
12 in Eqs. 17 and 18, we get another expression for the concentration in dialysate: 
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(34) 
and for the concentration in plasma water: 
(35) 
The ratio of the diffusive mass transfer ooefficient to the volume flux is obtained 
from Eq. 34, using c'" = 0: 
l/2 in[ (Qw;- Q,)Q"l -in[ Q., ·C,,- Qwi ·Cw;l 
K, ~ ·Q., Qw;(C,,- Cw;) 
n=--=------~--~--~~~~~~--
Jv in[ (Qw; Q,)Q.,] 
~-~ 
(36) 
K, values calculated by using Eq. 36 are slightly higher than those calculated by 
using Eq. 33. 
lf K, is known and C,, must be calculated, we use the formula derived by van 
Geelen [16]: 
(Q .j() \n•l- (() /() )n•l 
C = C . • Wl "<coo Xwo "<di 
'' M (Qw;/Q.;)n _ (Q • .J~r' (37) 
COMMENTS 
Two models have been described, the numerical and the analytical model. The 
numerical model describes the process more clear. However, use of the numerical 
model is more time-consuming. It may best be combined with the analytically 
derived expression of K, as an initial estimation to start the approximation procedure. 
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The analytical model bas a few limitations. It is only applicable for S=l andF=l. 
This poses no problems when the model is used to study the transport of uremic 
toxins. Analysis of the consequences of the assumption that Jv is constant rather than 
decreasing along the length of the dialyzer on the calcnlated value of K,, turnS out 
to be not significantly differem [17]. The analytical model presented here, cannot be 
used to calcnlate backfiltration from dialysate to blood. It is not applicable to protein-
bound solutes, unless it is assumed that protein binding is irreversible, i.e. C. can be 
substituted by C. ·F. 
A possible source of error in both the numerical and the analytical model is that 
'unstirred layer effects', which wonld lead to an influence of the axial flow rates on 
the concentration gradient, are not taken into account. 
In the next chapter, data are presented showing that, with low and variable 
dialysate flow rates, there is an appreciable effect of dialysate flow rate on the 
calcnlated value of K,. A correction for this effect will be suggested in the following 
chapter. 
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VALIDATION OF TilE MATIIEMATICAL MODEL OF 
CONTINUOUS ARTERIOVENOUS HEMODIAFILTRATION: 
THE ASSUMPTION OF MIXING CUP CONCENTRATIONS 
INTRODUCTION 
In the previous chapter, a mathematical model of solute transpon in CA VHD was 
presemed. In this model a number of assumptions were made. The most imponant 
assumption was the so called 'mixing cup' concentrations within both the blood and 
dialysate companment. Assuming mixing cup concentrations is valid when 
companments are well stirred, a condition which could be approached if flows are 
turl:lu!ent, but at least in the blood companment, flow is laminar. 
The true driving force for diffusion is the solute concentration gradiem over the 
membnme, which may be equated with the difference between the solute 
concentration in blood and dialysate close to the membnme. In both the numerical 
and analytical model, these concentrations are approached by taking the bulk or 
'mixing cup' concentrations in blood and dialysate (Figure la). This assumption 
implies that possible radial concentration profiles within either of the respective 
companments are not taken into account. However, solute concentrations close to the 
membnme may be different from mixing cup concentrations, thereby inducing a 
radial concentration profile. It is evident that a concentration difference between the 
area close to the membnme and anywhere else in the blood or dialysate companment 
will be generated by solute diffusion from blood to dialysate (Figure lb) [6]. With 
assuming mixing cup concentrations, the concentration gradient over the membnme 
will be overestimated and K, may be underestimated. Aiso, the solute concentration 
in the blood companment can be higher near the membnme, as will be described 
below. Then, with assuming mixing cup concentrations, the concentration gradient 
over the membrane will be underestimated and K, values may be overestimated. 
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cone. 
Cp Cm 
blood comp. dialysate comp. 
membr. 
Figure I a. Illustration of mixing cup concentrations on both sides of the membranes. 
In both the blood and dialysate compartment, no gradient of concentration is 
regarded. Concentration difference over the membrane is calculated from 
concentrations in blood (C) and dialysate (C,J. Cm: concentration in the 
membrane. 
cone. 
Cp Cm 
' .... _:~----
l.-,o-o-d _c_o_m_p __ _,--+--dl-al-y-sa_t_e _c_o_m-p. 
membr. 
Figure 1 b. Illustration of a possible concentration profile in both the blood (C) and 
dialysate compartment (C,J due to diffusion from the blood to the dialysate 
compartment and due to concentration boundary layer formation. em: 
concentration in the membrane. 
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Factors influencing the radial concentration profiles 
A radial concentration gradient can be influenced by blood and dialysate flow rates. 
In the blood compartment, as blood flow in the fiber is laminar, the distribution of 
solutes over the fiber is not homogeneous (i.e. concentration boundary layer 
formation) [6]. Accordingly, the difference berween the concentration in the middle 
of the stream and that near the membrane may be expected to depend on the blood 
flow rate. Furthermore, with low blood flow rates, an inhomogeneous blood flow 
distribution might occur. Within the dialysate compartment, due to diffusive 
transport, the concentration near the membrane is higher than that more distant from 
the membrane. Furthermore, with low dialysate flow rates, a 'stagnant' fluid layer 
surrounds the fiber, which is not mixed with fresh dialysate. Within this layer, solute 
concentration is higher than more distant from the membrane. Therefore, this layer 
adds to the resistance to diffusion. At higher dialysate flow rates, the stagnant layer 
will dimiuish and the solute concentration in dialysate near the membrane will 
decrease until, at an infinitely high dialysate flow rate, no stagnant layers exist. 
Thus, the axial flow rates may be expected to have an influence on the radial 
concentration gradient and thereby on the driving force for diffusion. As a result, 
when axial flow rates are changed, the calculated value of the mass transfer 
coefficient of diffusion (K,) may also be changed [1, 2]. 
The influence of ultrafiltration rate on the solute concentration gradient during 
CA VHD has not been previously studied. It is, however, conceivable that, in case of 
ultrafiltration, dragging leads to a higher blood solute concentration near the 
membrane [4, 7], which would enhance diffusive transport (Figure lc). On the other 
hand, ultrafiltration leads to an increased concentration of proteins near the 
membrane. This 'protein boundary layer formation' (protein concentration 
polarization) may lead to diminished membrane permeability and may thereby 
dimiuish transport by diffusion and convection. 
By the assumption of mixing cup concentrations the possible influences of axial 
flows and of ultrafiltration on diffusion gradients are neglected. We are, therefore, 
faced with the question whether changes in blood- or dialysate flow rate and changes 
in ultrafiltration flow rate have an influence on the calculated value of K., based on 
the simplified model. In the present study we therefore measured solute clearance and 
calculated K• values at different blood, ultrafiltration and dialysate flow rates. 
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Co 
blood comp. 
', Cd 
-- -'---------
: dialysate comp. 
membr. 
Figure 1 c. Illustration of a possible influence of ultrafiltration on the solute 
concentration gradient in the blood compartment. Solutes are dragged along 
with the ultrajiltrate and near the membrane a concentration build up will 
occur. 
PROTOCOLS 
Studies were perfonned during CA VHD in the Intensive Care Unit. Some additional 
studies were perfonned in the laboratory. The clinical procedure has been described 
in Chapter 4. The study protocols are described below. 
I. Blood flow rate (clinical observations) 
This protocol was aimed at studying the effects of blood flow rate (Q,) on calculated 
I<. values. The protocol was perfonned if the spontaneous blood flow through the 
filter was higher than 100 ml/mln, because blood flow rate could only be decreased 
by clamping of the blood line. Pressures, spontaneous blood flow rate and 
ultrafiltration flow rate (Q,) were measured two times, at the beginning and at the 
end of the experiment At each experiment, by clamping the arterial or venous line, 
blood flow was lowered 4 times to varying degrees and in random order. Dialysate 
flow rate (Q,) was set to 3 L/hr. Ultrafiltration flow rate was measured at each blood 
flow setting. Data were obtained with the AN-69, 0.6 m2 capillary dialyzer (Hospal, 
Multiflow-60). 
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II. Ultrafiltration/low rate (clinical observations) 
This protocol was aimed at studying the effect of ultrafiltration flow rate on 
calculated K, values. At each experiment, the ultrafiltration flow rate was changed 
5 rimes, in 1 experiment 3 rimes, by increasing or decreasing the height of the 
ultrafiltration column. Dialysate flow rate was set to 2 L/hr. Pressures, blood flow 
rate and ultrafiltration flow rate were measured two rimes, at the beginning and at 
the end of the experiment. Data were obtained with the AN-69, 0.6 m2 capillary 
dialyzer (Hospal, Multiflow-60). 
!II. Dialysate flow rate (clinical observations) 
This protocol was aimed at studying the effect of dialysate flow rate on calculated 
K, values. After measuring pressures, blood flow rate and ultrafiltration rate, 
dialysate flow rate was set to 0.5, 1, 2 and 3 L/hr. At each dialysate flow rate 
samples were taken from blood and dialysate (see below). Data were obtained with 
the AN-69, 0.6 m2 capillary dialyzer (Hospal, Multiflow-60), with the AN-69, 023 
m2 plate dialyzer (Hospal) and with a polysulfone 0.23 m2 capillary dialyzer (Solin 
HFT02). Details on dialyzer geometry are given in Chapter 3 and 4. 
IV. Laboratory protocol 
In the laboratory, measurements of solute transpOrt were performed at blood flow 
rates of 50, 100 and 200 ml/min and dialysate flow rates of 0.5, 1, 3 and 5 L/hr at 
a fixed ultrafiltration rate of 2 L/hr. Ultrafiltrate, collected during clinical 
hemofiltration, was used for blood substitute. Data were obtained with the AN-69, 
0.6 m2 capillary dialyzer (Hospal, Multiflow-60) for creatinine and phosphate. 
Sampling of blood and dialysate 
Samples were taken from the arterial line and from spent dialysate. In the clinical 
studies, arterial samples were taken at the beginning and at the end of the 
experiments. Concentrations in between were derived by linear interpolation. In the 
laboratory, samples from the blood inlet and outlet were taken at each flow rate. 
Dialysate samples of the outlet were taken at each sening of dialysate, blood or 
ultrafiltrate flow rate. They were taken after equilibration for a rime span that secured 
the passage of at least 500 m1 of dialysate fluid, i.e. 10 rimes the content of the 
dialysate compartment. In each sample, concentrations of urea, creatinine and 
phosphate were determined and in blood samples total protein concentration and 
hematocrit were determined as well. 
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TECHNIQUES OF MEASUREMENT 
Arterial and venous line pressures were measured electronically and dialysate 
pressure was calculated from the ultraiiltrate column height Blood fo;w rate was 
measured in triplicate by air bubble displacement In the clinical studies where blood 
flow rate was varied, it was measured both by air bubble displacement and by the 
echo transit time technique, using the Transonics• Clamp-on flowmeter [5]. Both 
methods yielded similar values. In the laboratory studies blood flow rate was 
measured by means of an electromagnetic flow probe. Dialysate foJw rate and 
ultr<ifiltration rate were measured by electronic weighing and by timed collection. 
CALCULATIONS 
Hydraulic permeability index (MI, [ml · hr"1 • mmHg-1]) was calculated as: 
Q ·60 
Ml=-'- (1) 
TMP 
where TMP is transmembrane pressure difference, calculated as described in Chapter 
4. The filter resistance to bloodfltJW (R,, [mmHg ·min · ml"1]) was calculated as: 
(2) 
where P, and P, are the hydrostatic pressures at the inlet and outlet of the filter 
respectively. lf R, was higher than 0.40, clotring of the filter may be the case. For 
this reason, l out of 6 experiments in protocol II and 5 out of 45 experiments in 
protocol III were discarded. 
The moss transfer coefficient of diffusion (K., [pm!min]) was calculated by using the 
analytical expression given in Chapter 5: 
In[ Q,, . c,, - Q"" • c"" l 
K, Q"" (C,, - C"") 
n =- = --..,.,,.-...,_=--
J. ln[ (Qwi- Q,)Q,,l 
Qwi ·Q. 
l (3) 
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The relationships between blood, filtrate and dialysate flow rates and K, were 
examined in two ways. First, we plotted K,. as a function of flow rate and performed 
linear regression analysis if applicable. Second, we used !he approach suggested by 
Wilson [6] (see below). The reciprocal of!(,., i.e. !he total resistance to diffusion (R, 
[min!pm]) is !he sum of !he resistances exerted by !he blood compartment (R,), by 
!he dialysate compartment (R,) and by !he membrane (R,J [8]: 
(4) 
According to Wilson, !he influence of dialysate flow rate on !he resistance to 
diffusion of the dialysate compartment may be examined by plotting the total 
resistance to diffusion as a function of Q, to the power -y, where !he value of y is 
empirically determined so as to yield a straight line. The y-intercept is taken to 
represent R,+R, (see Figure 2). We likewise defined the total resistance to diffusion 
as follows: 
(5) 
where a · Q;' represents R,, b • Q,·Y represents R, and c represents R,. a, b, c, x 
and y are positive values, to be determined by linear regression analysis. Eq. 5 
indicates that an increase of blood or dialysate flow rate results in a decrease of the 
resistance to diffusion, i.e. an increase of K, (see also ref [3]). 
0.03 1/Kd m1n/um 
Ml=:8.3 
1/Kd"' 1/113 ... 0.14/0d . . 
. 
, 
0.02 
. 
... ·} 
_.---- Rd 
.•. 
0.01 --· __ .-
0.00 
} Rb•Rm 
0.00 0.03 0.06 0.09 0.12 0.15 
1/0d m1n/ml 
Figure 2. Example of a Wilson plot and the regression junction obtained by linear 
regression analysis on data poims slwwn. 
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RESULTS 
I rifluence of blood flaw rate 
In protocol I, initial blood flow rate ranged from 10510 195 ml/min. Filters had been 
used for 1 to 97 hours and MI ranged from 3 to 28 ml • hf1 • mmHg·'. During the 
experiment R, did not change. With two filters that had been used for less than two 
hours, MI decreased by one fifth of the initial value. 
Figure 3 shows K. values at different blood flow rates. There was no apparent 
relationship. With linear regression analysis of K. as a function of Qb, 11 out of 13 
slopes were not sigcificantly different from zero (2 SE) and, of the remaining two, 
one slope was positive and the other slope was negative. The average slope was 0.00 
(see Table 1). 
Table I. Effects of changes in blood and ultrafiltration flow rates on the mass 
transfer coefficient of diffusion of creatinine (K.J and that of the reciprocal 
of dialysate flaw rates on the resistance to diffusion of creatinine (R). 
Results of regression analyses. n=number of experiments. 
MF-60: AN-69, 0.6 m2 capillary dialyzer (Multijlow-60, Hospal, France). 
HFT02: 0.23 m2 polysulfone capillary dialyzer (HFT-02, Sarin, Italy). 
CJ: Corifidence Interval. 
Flow range protocol 
ml/min 
Dialyzer n Slope 95% CI 
)ll1l/ml of the mean 
!(, VS Q,: 
19-195 Clinic MF-60 13 0.00 -0.06- 0.06 
50-200 Laboratory MF-60 3 0.00 -0.01 - 0.00 
K, vs Or: 
2-14 Clinic MF-60 5 0.06 -1.04- 1.16 
RvsQ;': 
8-50 Clinic MF-60 15 0.16 0.14- 0.18 
8-85 Laboratory MF-60 4 0.19 0.17- 0.21 
8-50 Clinic Plate 11 0.11 0.!0- 0.12 
8-50 Clinic HFT02 14 0.11 O.o7- 0.15 
76 
Chapter 6 
Influence of ultrafiltration rate 
In protocol !I, initial ultrafiltration flow rate ranged from 6 to 11 ml/min. Filters had 
been used for 12 to 18 hours. Values of the hydraulic permeability index ranged 
from 11 to 14 nil • br'1 • mmHg·1• 
Figure 4 shows K,. values at different ultrafiltration rates. Again, with linear 
regression analysis, slopes were not significantly different from zero (2 SE). The 
average slope was 0.06 pm/ml (see Table 1). 
Influence of dialysate flow rate 
In protocol III, MI ranged from 3 to 21. As shown in Figure 5, K,. increased to a 
maximum value with dialysate flow rates. Similar observations were made with the 
AN-69 0.6 m2 capillaty dialyzer (n=l5 experiments), the 0.43 m2 plate dialyzer 
(n=l!) and the po1ysulfone 023 m2 capillaty dialyzer (n=14). 
For creatinine, the influence of dialysate flow rate was quantified according to 
Eq. 5 (see CALCULATIONS). Slopes obtained from the regression analysis ofR as 
a function of Q,·' were all significantly different from zero (2 SE). The correlation 
coefficients (r) of the regression lines ranged from 0.91 to 1.00. 
Both with the AN-69 capillary and plate dialyzers, the intercept of the regression 
line proved to be related to MI (Figure 6), whereas with the polysulfone capillary 
dialyzer this relationship could not be determined. For the AN-69 capillary dialyzer, 
we performed linear regression analysis on the intercept as a function of the 
reciprocal of MI (r=0.76). As the intercept equals the minimal resistance to diffusion 
obtained with infinite dialysate flow rates, the intercept was defined as the reciprocal 
of I<._. The relationship between K""'= of creatinine and MI was given by: 
MI K"""'=u·160 (forMI<12) K,._=160 (forMI::12) (6) 
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Figwe 3. Diffusive mass transfer coefficient of creatinine (K,J for the AN-69 
capillary dialyzer as a junction of blood flow rate (Q,J. Each line 
represents one experiment. 
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Figwe 4. Diffusive mass transfer coefficient of creatinine (K,J for the AN-69 
capillary dialyzer as a junction of ultrafiltration flow rate. Each line 
represents one experiment. 
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Figure 5. Diffusive mass transfer coefficient of creatinine (K.J for the AN-69 
capillary dialyzer as a function of dialysate flow rate. Each line representS 
one experiment. 
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Figure 6. R.+Rm of the AN 69 capillary dialyzer for creatinine as obtained from 
regression analysis on Wilson plots as a function of hydraulic permeability 
index of membrane (Ml). 
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Results from laboratory experiments 
Results from the laboratory experiments were in accordance with clinicaUindings. 
The average slopes obtained from linear regression analysis of K.. as a function of 
Q, and that obtained from the regression of R as a function of Q,"1 are given in 
Table 1. 
In all experiments, K.. values of urea and phosphate were closely related to the 
corresponding values of creatinine. The ratio of the K.. value of urea to that of 
creatinine averaged 1.32 (SEM=4, n=l09) and the ratio of K.. of phosphate to that 
of creatinine averaged 0.75 (SEM=3, n=l25). 
DISCUSSION 
With our model of combined convection and diffusion, we calcnlated the mass 
transfer coefficient of diffusion (K,) based on the assumption of mixing cup 
concentrations. In the present study, we examined whether the same value of K.. may 
be used to extrapolate to solute clearance at different settings. We found that blood 
flow rate and ultrafiltration flow rate have no measurable influence on K,.. 
Accordingly, one may indeed use the model to predict solute clearance at blood flow 
and ultrafiltration rateS, different from those during the experiment in which K.. was 
determined. On the other hand, dialysate flow rates (Q,) does have an influence on 
K,.. Thus, when dialysate flow rate was increased from 0.5 to 3 L/hr, K.. values 
increased by approximately 100%. The effect of the dialysate flow rate on K. was 
analyzed as described by Wilson [6]. The 'Wilson plots' allowed us both to estimate 
R,+R.. and R• separately. The increase of K. with increasing Q, may be explained 
by the existence of an unstirred layer in the dialysate compartment, or, at low 
dialysate flow rates, the distribution of dialysate over the compartment is inadequate, 
resulting in a partial use of the membrane surface area. Therefore, the increase of K.. 
with increasing Q,, which may be ascribed to thinning of that unstirred layer in the 
dialysate compartment or an increase in the use of the membrane surface area, was 
quantified by a mathematical expression. Also, with the AN-69 dialyzers, K.. proved 
to be dependent on the hydraulic permeability index of the membrane (MI). Changes 
inK.. with different values of MI are contributed to a vatiability of R,+R,.. As was 
shown in Chapter 4, MI decreases over rime, probably due to protein absOiption. 
Therefore, the vatiability of R, +R,. may be caused by changes in R,. due to protein 
absorption on the membrane, whereas R, is not variable. This explanation is 
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supported by the results of protocol L Also, the influence of MI on K, was quantified 
by a mathematical expression. By incorporating the mathematical relation ofK, with 
both Q, and MI, one may allow for the influence of these parameters on K,. This 
maneuver should allow to extrapolate to solute clearance at different dialysate flow 
rates and at different values of MI. Thus, for the AN-69 capillary dialyzer the 
predicting formula of K, of creatinine becomes: 
_l_ =R =-1-+ 0.15 ·Q;1 
K, K"""" 
(7) 
in which K"""" is given by Eq. 6. 
Since values of K, of other solutes showed a fixed relationship with the value of K, 
of creatinine obtained from the same experiment, this relationship can be used to 
estimate K, of other solutes as welL 
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PREDICTION OF THE SOLUTE MASS TRANSFER 
COEFFICIENT OF DIFFUSION AND THE SOLUTE 
CLEARANCE RATE IN CONTINUOUS ARTERIOVENOUS 
HEMODIAFILTRATION 
INTRODUCTION 
The mass lrllllSfer coefficient of diffusion (K,, [pm!min]), as calculated by our 
mathematical model of combined convection and diffusion, was found to be related 
to the hydraulic permeability index of the membrane (MI, [ml • hr"1 • mmHg-1]) and 
dialysate flow rate (Q,, [ml/min]). This relationship was mathematically expressed 
as: 
l l 0.15 
-=--+--K, K"""' Q, 
(1) 
where ~ of creatinine is given by: 
MI K"""' = lZ · 160, For MI < 12: K"""" = 160, For MI:: 12 (2) 
1n addition, a fixed relationship was found between K. of creatinine (K,J and that 
of urea (K.,) and that of phosphate (K,,): 
(3) 
1n the present chapter, we examined whether these formulas may be used to 
obtain a reliable prediction of K, and solute clearance rate (Cl, [ml/min]). 
Furthermore, nomograms were constructed to facilitate these predictions in the 
clinical setting. 
Input values for the prediction of K. are dialysate flow rate and MI. For 
prediction of the clearance rate the value of plasma water flow rate at the filter iulet 
(Qwi, [ml/min]) must be known. As both values of MI and Qwi are not routinely 
measured in the clinic, formulas were constructed to estimate these values. 1n this 
way, prediction of clearance rates are more easily to perform in the clinical setting. 
Graphics were created to read the value of MI from the value of the ultrafiltration 
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flow rate and the value of Qwi from the value of the mean arterial pressure of the 
patient. The influences of errors resulting from these estimations on the prediction 
of K,. and MI were calculated. 
METIIODS 
Data were obtained from several clinical experiments, i.e from the experiments 
described in Chapter 6 and from the measurements of clearance rates of drugs (see 
Chapter 8), in which creatinine, urea and phosphate were measured simultaneously. 
All data were obtained with the AN-69 capillary dialyzer. Hydraulic permeability 
index of the membrane, resistance to blood flow of the dialyzer (R, [mmHg ·min 
• m1·1]) and ultrafiltration flow rate (Q,, [ml!min]) were measured as described in 
Olapter 4. Dialysate flow rate was checked by an electronic weighing device. If the 
resistance to flow was higher than 0.40, data were discarded. The mass transfer 
coefficient of diffusion was calculated using the analytical expression as described 
in O:tapter 5 (Eq. 33). K,. values of creatinine were predicted according to formulas 
1 and 2 and that of urea and phosphate according to formulas 1, 2 and 3. 
In accordance with our model, we defined solute clearance rate as: 
" ·C Cl _ "'<do .::lo 
c"' 
(4) 
where Q,. and c,. are flow rate and solute concentration at the dialysate outlet side 
of the dialyzer respectively, and Cw; is the solute concentration in plasma water at the 
blood inlet side of the dialyzer. aearance rate was predicted by substituting the 
predicted value of K,. in the followiog formula derived by van Geelen [1]: 
a- . (Qw/Q,.r 1 - (Qw.fQ..r 1 
- Q,. (~/Q,,)"- (Q..JQ,)"'l (5) 
where n is K,. • S!Q, S is membrane surface area, Qwo the plasma water flow at the 
dialyzer outlet and Q.. and Q.. are dialysate flow rates at the dialyzer inlet and outlet 
respectively. For both K,. and a, lioear regression analysis was performed on the 
observed values as a function of the predicted values and 95% confidence intervals 
were detemtined. 
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A nomogram was constructed to obtain the value of plasma water flow from the 
observed mean anerial pressure of the parient (MAP, [mmHg]) according to the 
following formula: 
MAP-P. Qwi = 
0
_
44 
,. ·(1-Ht) ·(1-0.00107 ·C,.) +f·Ht (6) 
where the intravenous pressure of the patient (P,., [mmHg]) was taken to be 10 
mmHg, hematocrit (Ht) 0.30, total protein concentration in plasma Cc,.J 50 g/dl, the 
fractional volume distribution of solutes in blood cells (!) zero and the total 
resistance to flow of the catheterS and the dialyzer was taken to be 0.44, which 
equals mean observed values (see Chapter 4). Note that, if predilution is used, the 
value of the predilution flow rate has to be added up to the plasma water flow rate. 
For errors in the estimation of Qwi up to 50%, the resulting error in the value of the 
predicted clearance rate was calculated for Q,=l L/hr, MI=8 and Q,=8 ml/min. The 
value of Qwi and that of clearance rate at 0% error (startiug value) were 100 ml/ntin 
and 22 ml/min respectively. 
Furthermore, a nomogram was constructed to obtain a value of MI from the 
observed values of Q, in ml/br and MAP according to the following formula, 
assuming equal values of the resistance to flow of both the catheters: 
Q, 
Ml=~~~~-----­MAP+P. 
--..,..--'" + P, - COP 
2 
(7) 
where the pressure in the dialysate compartment (P,, [mmHg]) was taken to be -37, 
which is obtained with an ultrafiltration column height of 50 em and the colloid 
osmotic pressure (COP, [mmHg]) was taken to be 20. Accordingly, for errors in the 
estimation of MI up to 50%, the resulting errors in the predicted value of K., for 
Q,=l and 3 L/hr were calculated by using Eq. I and 2 (startiug value of MI=8). 
Then, the impact was detennined of an underestimation and overestimation of K., up 
to 50% on the predicted clearance rate for Q,=8 ml/min and Q~=IOO ml/min. 
Herewith, startiug values of K., were predicted for Q,=O.S, 1 and 3 L/hr and MI=8. 
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Figure I. Expected plasma water flow rate as a junction of mean arterial pressure 
(zero pre dilution flow rate and f=O ). 
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Figure 2. The error in terms of percentage in predicted clearance rates of creatinine 
as a junction of an error in terms of percentage in the estimation of Qw,· 
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RESULTS 
From Figure 1, one can read the expected value of Qw; by using the mean anerial 
pressure of the patient as input value. This Figure is based on values of the mean 
observed resistance of flow of the catheters and of the filter. Figure 2 shows the 
consequences of underestimation or overestimation of Qwi on clearance rate. In Figure 
3, the value of MI can be read from ultrafiltration flow rates for MAP values of 50, 
70, 90 and 110 mmHg. Figure 4 shows the effect of an error in terrns of percentage 
in MI on the prediction of K. for Q.,=1 and 3 L/br. The absolute error and the error 
in terrns of percentage in clearance rates effected by an error in the predicted value 
of K. are shown in Figures 5 and 6 respectively. Staning values forK. were 35, 55 
and 81 pm/min at 0.,:0.5, 1 and 3 L/hr respectively. Figures 7 and 8 show the 
observed values of K, and Cl respectively of creatinine as a function of predicted 
values. The coefficient of determination (r) ofK. of creathline was 0.73 (n=251) and 
that of clearance rate was 0.81 (n=255). For urea, these values were 0.70 (=233) 
and 0.80 (n=249) and for phosphate 0.58 (n=230) and 0.71 (=240) respectively. 
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Figure 3. Expected values of MI as a junction of ultrafiltration flow rate for mean 
arterial pressures of the patient of 50, 70,90 and 110 mmllg. 
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Figure 5. Predicted clearance rates of creatinine as a function of an error in terms 
of percentage in the predicted value of K,. 
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Figure 7. Observed values of K. of creatinine as a junction of predicted values and 
95% confidence intervals. Data obtained with the AN-69 capillary dialyzer 
at different operational conditions. 
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Figure 8. Observed values of creatinine clearo.nce rate as a function of predicted 
values and 95% confidence intervals. Data obtained with the AN-69 
capillary dialyzer at different operational conditions. 
DISCUSSION 
In 1his chapter the applicability of the prediction fonnulas of K., of creatinine, as 
derived in Chapter 6, was examined. It was concluded that 73% of the variability of 
K., of creatinine can be explained by variations in Q, and .MI. For prediction of K., 
values of urea and phosphate, the predicted value of the K., of creatinine was 
multiplied by the acocmpanying ratio. Comparing the predicted values of K., of urea 
and phosphate with the observed values demonstrate that respectively 70% and 58% 
of the variability could be explained. Therefore, it can be concluded that the use of 
a fixed relationship between K., of creatinine and that of other solutes is justified (Eq. 
3). The main purpose of predicting K.,, is to obtain an indication of the expected 
clearance rate at different operational conditions. As clearance in CA VHD takes 
place by combined convection and diffusion, prediction of values of clearance rates 
will always be more accurate than prediction of K., values. Therefore, explaining the 
variability in clearance rates was superior to that of K., values. 
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The contribution of diffusive transport to the total transport of solutes increases 
with dialysate flow rate. Therefore, as was shown in Figure 6, the error of the 
predicted clearance rate generated by an error in the predicted K, increases with 
dialysate flow rate. However, as the error in K, was calculated in terms of 
percentage, the absolute change was higher at high dialysate flow rates with 
accordingly high K, values. 
Since values of Qwi and :MI are not readily available, nomograms are constructed. 
An underestimation or overestimation of Qwi will induce a minimal error in the 
predicted clearance rate. Using an estimated value of :MI, the error in the value of the 
predicted clearance rate is minimized by using the observed value of Q,. In this way, 
an error in the estimation of :MI depends only on the estimation of the 
transmembrane pressure difference. (see Eq. 1, Chapter 6). The transmembrane 
pressure difference can be calculated from the MAP, and mean values of the P,,, the 
P,, and the COP. If the ultrafiltration column height is 50 em, the error in terms of 
percentage in :MI due to a deviation of P,, and COP from the values of 10 and 20 
mmHg respectively, will not be higher than approximately 10%. Thus, when using 
the observed value of Q, and MAP, errors in the estimation of :MI would not be as 
high as is shown in Figure 4. 
In conclusion, the prediction of clearance rates of different uremic solutes is 
feasible and can be simplified to be used in the clinical setting. In the next chapter, 
the feasibility of prediction of the clearance rate of drugs is examined. 
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DRUG CLEARANCE BY CONTINUOUS ARTERIOVENOUS 
HEMODIAFILTRATION: ANALYSIS OF 
SIEVING COEFFICIENTS AND MASS TRANSFER 
COEFFICIENTS OF DIFFUSION 
INTRODUCTION 
With CA VHD, time-averaged clearance rates may be several fold higher than with 
either CA VH or conventional dialysis techniques. With the latter two techniques, it 
is known that some drugs are cleared to a significant extent [1-4]. Therefore, with 
CA VHD drug clearance rates may be high enough to warrant dosage adjustments. 
To determine dosage adjustments, insight into the determinants of transpon is 
needed. 
Clearance rate by CA VHD of uremic soluteS can be reliable predicted by our 
mathematical model of combined convection and diffusion. This model can be 
further extended to transpon of drugs. lmponant determinants of transpon of drugs 
are the sieving coefficient and the mass transfer coefficient of diffusion (K,, 
[pm/min]). They have to be experimentally determined. When the values of these two 
parameters are known. our model may be used to calculate drug clearance rates under 
a variety of operational conditions. ln this study, clearaoce rateS of urea, creatinine, 
uric acid, phosphate and of the antibiotics cefuroxime, cefotaxime, ceftazidime, 
imipenem, ciprofl.oxacin, tobramycin and vancomycin are measured in patients who 
were treated with CA VHD. 1n patients receiving imipenem, concentrations of 
cilastatin were measured too. By using the numerical mathematical model of 
hemodiafiltrarion (see Chapter 5), the data were analyzed in terms of sieving 
coefficients and mass transfer coefficients of diffusion. The relationship between K, 
values of creatinine and K, values of drugs were determined. 
METHODS 
The clinical protocol is described in Chapter 4. Drugs were given as clinically 
indicated. lf an antibiotic was prescribed, the patient was eligible for this study. 
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Study protocol 
First, the infusion pumps for dialysate and substitution fluid were turned off. The 
dialyzer condition was established by measuring the resistance to blood flow (R,, 
[mmHg • ruin/ml]) and the membrane hydraulic permeability index (MI, [ml/h • 
mmHg]). Samples of blood and ultrafiltrate were taken to determine the drug's 
apparent sieving coefficient (see Calculations) and the free fraction. Then, the 
substitution fluid infusion pump was turned on and samples of blood and ultrafiltrate 
were taken again. After that, the dialysate flow rate was set to 1 L/hr. Dialysate 
samples were taken to determine clearance rates and diffusion coefficients of 
creatinine, urea, uric acid, phosphate and of the drug. The same procedure was 
repeated at a dialysate flow rate of 3 L/hr. Samples were taken after equilibration for 
a time span that secured the passage of at least 500 ml of ultrafiltrate or dialysate 
fluid, i.e. 10 times the content of the dialysate comparnnent Finally, the dialysate 
pump was turned off and Ml and R, were determined again. The study protocol 
implied blood sampling to a total volume of 35 ml, which is 20 ml in excess of the 
routine. 
Measurements 
Pressures in the arterial and venous blood line (P. and P., [mmHg]), pressure in the 
dialysate compartment (P., [mmHg]) and uitrafiltration rate (Q,, [ml/min]) were 
measured as described in Chapter 4. Dialysate flow rate at the inlet of the dialyzer 
(Q.u, [ml!min]) was checked using an electrouic weighing device. Blood flow (Q,, 
[ml/min]) was determined either by measuring the time required for air bubble 
displacement over a certain length of tubing containing a volume of 13 ml or by 
measuring the transit time of an echo signal, using the TransouicsR HT101D 
flowmeter with a clamp-on probe around the blood line [5]. Both methods yielded 
similar values. 
When the dialyzer condition was poor, i.e. when the resistance to blood flow 
was higher than 0.40 mmHg · min • ml"1 and/or ultrafiltration rate was less than 
175 ml/min, the data were discarded. 
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Calculations 
The dialyzer resistance to flow and the hydraulic petmeability index of the membrane 
were calculated as described in Chapter 4. The sieving coefficient (s) was calculated 
as: 
2 ·C, (1) 
with C, the drug concentration in ultrafiltrate, and ~ and C,., the drug 
concentrations in plasma water at the blood inlet and outlet respectively (for 
calculation of ~ and C,., see Chapter 5). Note that this is the clinical definition of 
the sieving coefficient, which is equivalent with the physical definition of 'apparent' 
sieving coefficient. The true sieving coefficient, i.e. the fraction of non protein bound 
solute that passes through the membrane during ultrafiltration, is taken to be one. 
With high flux membranes, this assumption is valid for solutes of up to several 
thousand Daltons. The apparent sieving coefficient of a solute, s, as calculated 
according to Eq. 1, i.e. the product of the true sieving coefficient and the free 
fraction should then be equal to the free fraction. 
Clearance (Cl, [ml!min]), defined as the rate of mass transfer divided by the total 
concentration in plasma at the blood inlet, was calculated as: 
(2) 
Where Q., and C,, are flow rate and solute concentration at the dialysate outlet of 
the dialyzer respectively, and Cp; is the solute concentration in plasma at the blood 
inlet side of the dialyzer. 
From the observed flow rates and solute concentrations, K., was calculated using the 
numerical model as described in Chapter 5. 
Drug assays 
Blood samples were centrifugated and the plasma was stored at -80'C. Total (bound 
plus free) drug concentrations were measured in plasma and in filtrate 1 dialySate. 
Concentrations of tobramycin and vancomycin were detetmined by a fluorescence 
polatization immunoassay [ 6]. The day to day variability of the assay of tobramycin 
was 4% and that of vancomycin 7%. Concentrations of cefuroxime, cefotaxime, 
ceftazidime, imipenem, ciprofloxacin and cilastatin were detetmined by H.P J...C. [7-
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11] with slight modifications. The day to day vatiability of the H.P .L.C. assay was 
6% for cefuroxime, 7% for cefotaxime, 7% for ceftazidime, 7% for imipenem and 
5% for ciprofloxacin. 
To detennine drug protein binding, plasma samples were centrifuged through a 
porous membrane of regenerated cellulose (Centri-free system, Amicon, U.S.A.) with 
a molecular cut-off of 30, 000 Daltons. The free fraction was calculated as the ratio 
of the concentration in the filtrate to that in plasma water. Protein binding of 
imipenem was not detennined, since plasma samples containing imipenem were 
immediately stabilized by buffering to pH 6.5, by which protein binding is reduced. 
Protein binding of ciprofloxacin was not determined. 
Table 1. Range of drug clearance rates during CAVH and CAVHD. 
1
: Total of measurements ar dialysareflow of I Uhr and 3 Uhr. 
DRUG n' Or Clcavh Cleavbd 
I L/hr 
ml/hr ml/min ml/min 
Cefuroxime 22 270-990 4-14 7-26 
Cefotaxlme 13 380-990 5-!3 9-20 
Ceftazidime 24 240-890 4-14 13-30 
Jmipenem 23 180-720 4-12 8-34 
Ciprofloxacin 4 410-490 7-8 18-23 
Tobramycin 30 240-880 3-12 13-24 
Vancomycin 6 330-740 4-8 8-20 
Cilastatin 24 200-720 2-9 6-20 
RESULTS 
ClClJ.Vbd 
3 L/hr 
ml/min 
10-42 
17-25 
17-38 
17-49 
24-39 
17-32 
11-20 
7-24 
The study protocol was performed 53 times in 32 patients with 19 dialyzers. With 
9 protocols, the patient received two different antibiotics. Therefore, the total amount 
of measurements of clearance of antibiotics was performed 62 times, each 
measurement at two dialysate flow rates. Due to time the protocol needed to be 
performed, sieving coefficients were not detennined at every protocol. Both for 
cefotaxime and ciprofloxacin, sieving coefficients were detennined two times 
separately and at one of these occasions, clearance rate of cefotaxime was measured 
only at a dialysate flow rate of 1 L/hr. For imipenem, at one protocol, the 
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concentration of spent dialysate at a dialysate flow rate of 3 L/br was too low to 
detennine reliably and for tobramycin tbis occurred at 1 protocol for both dialysate 
flow rates. Blood flow tate was 125 (SD 32) ml/min and net ultrafiltration tate was 
540 (SD 225) ml/br. At a dialysate flow tate of 1 L/hr, urea clearance tate was 24 
(SD 4) ml/min and creatinine clearance was 21 (SD 5) ml/min. At a dialysate flow 
tate of 3 L/hr these values were 42 (SD 9) and 32 (SD 7) ml/min respectively. At 
the time of measurements, dialyzers had been used for an average time of 50 hrs 
(range 0.75-291 hrs). The hydraulic penneability index of the membrane and the 
resistance to flow have not changed during the expetiment. 
Ranges of drug clearance rates are presented in Table 1. Sieving coefficients, 
measured free fractions and free fraction of nonnals are presented in Table 2. 
The value of the sieving coefficient itself was not related to either the hydraulic 
penneability index of the membrane (MI) or to the rate of ultrafiltration (see Figure 
1). The sieving coefficient was not different from the corresponding free fraction, as 
detennined in the laboratory. The free fraction in our patients was, however, different 
from that in nonnal subjects (see Table 2). 
The value of K, of creatinine was 71 ± 30 (range 20 to 155) )IIll/min. This 
variability was largely explained by differences in membrane penneability, as 
reflected by the hydraulic penneability index, and by differences in dialysate flow 
tate (see Chapter 7). K, values of a number of solutes, expressed as a percentage of 
the corresponding K, of creatinine, are given in Table 3. Seventeen K, values of 
drugs resulted in negative values or an error. K, values were related to the solute 
molecular weight (see Figure 2). Regression analysis of the logarithm of K, as a 
function of the logarithm of molecular weight (MW, [Daltons]) yielded the equation: 
K, MW -OA2 
r=<m) 
,, 
(3) 
For some of the drugs, however, K, values were appreciably higher than expected 
according to the regression equation. Using ouly the mass transfer coefficient of 
antibiotics (n=7), regression analysis yielded an exponent of -0.44 (r=0.67). 
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Table 2. Comparison of free fraction and sieving coefficient. The sieving coefficient 
during CA VH is not different from the free fraction as determined in the 
lohoratory. Values of the measwedfreefraction and the apparent sieving 
coefficient in!CU patients were averaged to obtain the value of F. which 
will be used to predict clearance rates (see Chapter 9). 
DRUG Free fraction % sieving coeff. % F 
normals [ref] patients n patients n 
Cefuroxime 67 [18] 78±8 12 81 ± 10 21 0.80 
CefotaXime 60 [19] 77±7 9 76± 12 14 0.76 
· Ceftazidime 83 [20] 86±5 5 95± 5 12 0.92 
Imipenem 80 [21] 100 ± 14 22 1.00 
Ciprofloxacin 75 [22] 102±7 6 1.02 
Tobramycin 100 [23] 79±5 9 83 ± 7 19 0.82 
Vancomycin 45 [24] 56 1 68± 7 5 0.67 
Cilastatin 20 [25] 68± 2 20 0.68 
Siev. coeff. 
(actual/drug 1.3 ,-----
average) 
---------~ 
• • 
• <II 
• 
• • 
'· 
• • • • 
• 
• 
••• e 
e 
0.7 I~ 
0.5 '----- -·-- . - _ _I~ • -- ___ __~__ __ ---' 
0 5 10 15 20 25 30 
Membrane Index (ml/hr.mmHg) 
Figure 1. Relationship of the sieving coefficient qf drugs (s) with the hydraulic 
permeability index of the membrane (Ml). 
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Table 3. Solute molecular weight (MW) and mass transfer coefficient of diffusion 
(K,J expressed as a percentage of the co"esponding Kd of creatinine (K,.J. 
1 Estimated molecular weight in blood: At pH 7.40 with pKa 7 21, 39% 
is taken to be present as insoluble Ca(H,P04)2 and 62% as Ca(HP04). 
2 In-vitro data supplied by D. Pouchoulin, Hospal C.O.T., Lyon, France. 
SOLU1E M.W KJK.. SEM n 
% 
Urea 60 132 4 109 
Lactate 90 93 2 2 
Creatinine 113 100 
Uric acid 168 93 4 123 
Phospha!e 174' 75 3 125 
Vitamin B 12 1355 242 1 5 
Imipenem 317 68 8 20 
Ciprofloxacin 331 85 12 2 
Cilastatin 384 56 5 21 
Cefuroxime 424 72 7 21 
Cefotaxime 455 37 7 11 
Tobramycin 468 72 6 26 
Ceftazidime 547 66 6 22 
Vancomycin 1449 37 4 5 
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Figure 2. Relationship between Ka and solute molecular weight (MW). K, values 
were expressed as a fraction of the corresponding K, of creatinine (K.,). 
Numerical values are given in Table 3. 
Linear regression analysis of Ln(Kd I K.,) as a function of Ln(MW) yielded 
a correlation coefficient (r) of 0.87. 
DISCUSSION 
In the previous chapter, the feasibility of the prediction of the value of K, of 
creatinine based on dialysate fiow rate and the hydraulic permeability index of the 
membrane was demonstrated. To use this model for prediction of drugclearance, the 
ratio of K, of creatinine to that of the drug and the sieving coefficient of the drug 
was determined. The present study yielded two imponant results. 
First, it was demonstrated that a drug's apparent sieving coefficient may be 
equated to its non-protein bound fraction. The laner may be determined in the 
laboratory. Since, in patients, the non protein bound fraction may differ remarl<ably 
from values in normals, it would be worthwhile to have the free fraction routioely 
determined in a blood sample. The binding of acidic drugs may be decreased due to 
uremia, low levels of albuntio, high levels of bilirubin and free fatty acids or due to 
competition by other drugs [12-14]. The binding of basic drugs may be increased due 
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to increased levels of a,-acid glycoproteins, one of the acute phase proteins [15]. In 
general our data on sieving coefficients were roughly in accordance with data of 
several studies given by Bickley et a! [16] and Kroh et al [17]. 
Second, we found a relationship between I<aJK.o and solute molecular weight. 
With the AN-69 capillary dialyzer, drug clearance rates can now be predicted by the 
model as follows. First, dialysate flow rate and the membrane hydraulic permeability 
are determined for the estimation of K, of creatinine. Then K, of the drug is 
ealimated, either from published values of I<aJK.o (see Table 3) or from an estimation 
of K,IK,, based on the drug molecular weight. Then the free fraction, F, is either 
taken from published values or determined in the laboratoty. The values are used for 
input in the model, by which drug transpon may then be calculated for an average 
plastua water flow rate or ealimated from the mean arterial pressure of the patient. 
(the influence of differences in blood flow rate is small). The whole procedure will 
be demonstrated in Chapter 9, in which predicted values of clearance rate of drugs 
will be compared to observed values. 
It should be noted that the findings in this study are restricted to the dialyzer we 
used, the AN-69 capillary dialyzer. In case of other membranes with a smaller pore 
size or electric charge might cause the drug sieving coefficient to be different than 
its free fraction. Furthermore, it may be expected that the relationship between K, 
and molecular weight depends on the membrane resistance to diffusion and its 
contribution to the overall resistance to diffusion of the dialyzer. This methodology 
for the analysis of drug clearance by CA VHD, however, should be readily applicable 
to other dialyzers. 
In conclusion, this study shows the feasibility of determining free fractions and 
K, values of drugs. With these parameters the clearance duriog CA VHD may be 
predicted for different operational conditions. In the next chapter the reliability of 
such predictions will be examined and consequences for dosage adaptations will be 
considered. 
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DRUG CLEARANCE BY CONTINUOUS ARTERIOVENOUS 
HEMODIAFILTRATION: PREDICTION OF DRUG 
CLEARANCE RATE AND RECOMMENDED DOSE 
ADAPTATIONS FOR SEVEN ANTIBIOTICS 
INTRODUCTION 
In the previous chapter, clearance rates (Q, [ml!min]) hy CA VHD of different drugs 
were examined. Data were analyzed in tenns of sieving coefficients and mass transfer 
coefficients of diffusion (K., [pm/min]). The ratio of the mass transfer coefficient of 
diffusion of drugs to that of creatinine was detennined. As was shown in Chapter 6, 
clearance rates by CA VHD of uremic solutes other than creatinine could be predicted 
when the predicting formula of K.. of creatinine was extended by the ratio of K.. of 
the uremic solute to that of creatinine. In this chapter, the feasibility of predicting 
clearance rates of drugs, which have an apparent sieving coefficient lower than one, 
will be examined. 
As patients treated by CA VHD are nearly always anuric, the removal of drugs 
which are normally excreted by the human kidney can occur predominamly by 
CA VHD. This is especially true if the protein binding of the drug is low, if the 
volume of distribution is small and if the non-renal clearance rate is low in 
comparison to the clearance rate by CA VHD. If a drug meets the demands as stated 
above, treatment by CA VHD will warrant dosage adaptations. Most previous studies 
on clearance of drugs by continuous renal replacements techniques focused on 
CA VH [1-5]. Recently, some studies have been published on drug clearance by 
CA VHD [6-8]. However, little is known about the required dosage regimens of drugs 
during treatment by CA VHD. 
In the present chapter, drug clearance rates by CA VHD at different operational 
conditions are predicted and compared to observed values. Dosage adaptations are 
calculated for anuric patients treated by CA VHD at dialysate flow rates of 1 L/hr and 
3 L/hr. 
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METI!:ODS 
Prediction of K• and clearance rates of drugs 
Clearance rates of cefuroxime, cefotaxime, ceftazidime, imipenem, tobramycin, 
vancomyCin, ciprofloxacin and cilastatin were measured during CA VH and during 
CA VHD at a dialysate flow rate of I and 3 L/llr. The srody protocol as well as the 
analysis of data has been described in Chapter 8. 
The mass transfer coefficient of diffusion of drugs was predicted using the 
predicting formula of K., of creatinine as described in Chapter 6, multiplied by the 
ratio of K., of the drug to that of creatinine as given in Chapter 8. The mass transfer 
coefficient of diffusion was calculated by the numerical method as described in 
Chapter 5. 
Predicted values of drug clearance were calculated by inco~porating the predicted 
values of K., in the following formula: 
cQ,JQ.,r'- <Q..,JQ,r' Cl = Q, · · F ·1.05 
, <Q.JQ..!'- CQ.,tQ,.;r' (I) 
where n = K., • Sf~. S [m2] is membrane surface area, Q~ [ml!min] the plasma 
water flow at the dialyzer outlet, Q, and Q,, [ml/min] are dialysate flow rates at the 
dialyzer inlet and outlet respectively and F is the average of the apparent sieving 
coefficient and the free fraction of the drug concerned as given in Chapter 8, Table 
2. To calculate plasma clearance rate from plasma water clearance rate, the latter is 
multiplied by !.05, to account for the volume fraction of proteios. The whole 
procedure of calculating predicted values in the clinical setting is given in Figure I. 
Observed plasma clearance rates were calculated as: 
(2) 
Linear regression analysis was performed for both predicted K., values and clearance 
rateS by CA VHD as a function of the observed values aod 95% confidence intervals 
were calculated. 
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Example: Tobramycin ( K,/K,.,=0.72 F=0.82) 
1 P.=68mmHg 
11:= 20mmHg 
2 1MP = 51 mmHg 
Q,= 500 ml/br 
3 MI = !0 mlJlJr · mmHg 
P, = 32 mmHg P, = -30 crnHzO 
--> 1MP = 51 mmHg 
--> MI = 10 ml/br·mmHg 
Q. = 2 L/hr --> !(,. = 83 )lill/mi:n 
4 !(,. = 83 )lill/mi:n 
KJK., = 0.72 --> K, = 60 )lill/mi:n 
5 Q,. = !17 ml!min. Q. = 33 ml/min Q, = 8 ml/min 
Q,...=5ml!min 
f = 0 S = 0.6 m' F = 0.82 Ht = 030 C,.,, = 50 mg!L 
K, = 60 jllll/min 
(Eq. 2, Chp 4) 
(Eq. 6, Chp 4/ 
(Eqs. 6, 7, Chp 6) 
c¢ = 10 mmo!IL --> c" = 6 mmo!IL (Eq. 11, Chp 5) 
(fot procedure, see Figure !, Chp 5) 
6 Q, = 41 ml/min cdo = 6 mmol/L 
c~ = 10 mmol/L --> Clearance- 22 ml/min 
(Eq. 2, Chp 9) 
Figure I. Algorithm for the prediction of drug clearance rate in CAVHD. For 
abbreviations see previous chapters or abbreviationlist. 
·The value of Ml and Qw, can also be read from the nomograms (Chp 7). 
Dosage adaptations 
The drug half life (f.,Jl) during CA VHD treatment was calculated by using the 
formula: 
TB=0.693·V, 
"' --,a=--" 
(3) 
where V, is the distribution volume of the drug [9]. Values of drug protein binding, 
of dislribulion volume, and of total and non-renal clearance rates were taken from 
the literature (see Table l). If possible, all values, except the values of clearance rates 
in nonnals, were taken from studies, which obtained data from critically ill patients. 
Recommendations regarding dose adjustments were based on changes in the drug 
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clearance rates. For every drug, the average clearance rates by CA VHD at dialysate 
flow rates of I L/hr and 3 L/hr were used to calculate dose adaptations. A one 
compartment model of pbarmaccldnetics was used to calculate doses and dose 
intervals that led to the desired levels. Time related changes in drug ccncentrations 
were calculated according to: 
Cl• t 
C =C .~v;-
,, pO 
(4) 
where C,. is the initial plasma ccncentration, c;, is the plasma ccncentration after a 
time span t. Desired levels were deteiiDined by taking into account the drugs' mode 
of action and their toxicity [10-12]. Thus, for beta-lactams and imipenem, we aimed 
for plasma ccncentrations continuously above the minimal inhibitory concentration 
(MIC) of most ccmmon pathogens. For tobramycin the area under the curve (AUC) 
is probably the main deteiiDinant of efficacy [13]. Therefore, for this antibiotic, we 
aimed for high peak levels with trough levels low enough to reduce the risk of 
serious toxicity. For vancomycin the same strategy was followed. For ciprofloxacin, 
we aimed for high peak levels and trough levels not falling to low. 
RESULTS 
Figure 2 shows the correlation between the observed and predicted values of the K,. 
of all drug together (n=l20). The coefficiem of deteiiDination (r'-) was 0.42. Eight 
values were considered as outlayers. 
Figure 3 shows predicted values of plasma clearance rate versus observed values of 
each drugs separately. In Figure 4, the correlation between the predicted clearance 
rates and the observed values are given for all drugs together. The coefficient of 
deteiiDination was 0.64, n= 146. Values of ranges of drug clearance rates by CA VH 
and by CA VHD at a dialysate flow rate of l and 3 L/hr are given in Chapter 8. 
Average values± SD of clearance rates at a dialysate flow rate of 1 L/hr and of 3 
L/hr were for cefuroxime 15 ± 5 and 25 ± 9, for cefotaxime 14 ± 3 and 21 ± 3, for 
ceftazidime 18 ± 5 and 27 ± 6, for imipenem 18 ± 7 and 31 ± 9, for ciprofloxacin 
21 ± 2 and 26 ± 6, for tobramycin 19 ± 3 and 26 ± 4, for vancomycin 15 ± 4 and 
17 ± 4 and for cilastatin 12 ± 4 and 17 ± 5 ml/min respectively. 
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Figure 2. Comparison of observed values of K, of eight different drugs calclilaJed 
from membrane surface area, flow rates and drug concentrations, with 
values predicted from dialysate flow rare, membrane Jrydraulic 
penneabiliry and the ratio KjK"". The lines show the 95% cor{idence 
intervals. 
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Figwe 3. Clearance observed versus clearance predicted of each drug separaJely. 
Line of identity is given. 
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Figure 4. Clearance observed versus clearance predicted of eight different drugs 
together. The lines s!ww the 95% confidence intervals. 
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Table 1. Volume of distribution, clearance rates and half lives in normals and In anurlc patients with and without treatment by CAVHD. 
1 Data taken from literature. 
2 Sum of non-renal clearance rate and average clearance by CAVHD. 
3 Calculated by using Eq. 3 (body weight 70 kg). 
Drug V,' [Likg] Clearance [ml/min]: Half life [hrl) References 
nonnal1 anuric1 amrric an uric norrnal3 anuric3 an uric an uric 
CAVHD CAVHD CAVHD CAVHD 
I L/hr' 3 L/hr' I L/hr' 3 L!hr' 
cefuroxime 0.23 115 5 20 30 1.7 38.7 9.3 6.2 [30] 
cefotaxime 0.37 353 143 157 164 1.1 2.4 1.9 1.8 [31-35] 
ceftazidime 0.18 115 8 26 35 1.7 25.3 5.6 4.2 [33, 34, 36-38] 
imipenem 0.31 245 116 134 147 1.0 2.2 1.9 1.7 [4, 39-41] 
ciprofloxacin 2.61 521 254 275 280 4.3 8.2 6.4 6.2 [42] 
tobramycin 0.28 84 7 26 33 1.8 40.8 8.7 6.9 [43-45] 
vancomycin 0.35 121 <5 20 22 3.7 90.2 14.2 12.9 [46-49] 
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Mean drug clearance rates and corresponding plasma half lives are given in 
Table 1. Differences between the values of clearance rate and half lives in the 
untreated anuric state and duting treatment by CA VHD, were most pronounced for 
cefuroxime, ceftazidime, tobramycin and vancomycin In the anuric state, adjustment 
of drug dosage was necessary for all antibiotics. During CA VHD treatment, further 
adjustment was required for cefuroxime, ceftazidime, robramycin and vancomycin 
Results of cilastatin will be discussed in Chapter 10. Guidelines for drug dosage in 
patients with untreated anuria and in patients treated by CA VHD are given in 
Table 2. Since the volume of distribution may effect drug half-life, the volume of 
distribution was varied in the model. An increasing or decreasing of V, by 1.5 times 
did not affect the results in such a way that calculated dose or dose intervals needed 
to be adjusted. 
Table 2: Guidelines for dosage adjustment in CAVHD and the aimed peak and 
trough levels. 
1) Second and later administration: give haif the standard dose. 
2) Give haif the standord dose. 
3) Lean body mass 
4) Adjust dosage according to peak and trough levels, measured respectively one 
hour cifter start of the infusion and shortly before a new dose. 
Drug Standard Dose interval [his]: 
dose 
nonnal anuric anuric anuric peak trough 
CAVHD CAVHD level level 
1 L/hr 3 L/hr mg/L mg/L 
cefuroxime 750mg 6 48 12 12 
cefotaxim.e !OOOmg 6 8 8 8 
ceftazicfune lOOOmg 8 48' 12' 12' 
imipenem SOOmg 6 12 12 12 
ciprofloxacin 200mg 12 122 12' 12' 
tobramycin 3mgjklf 12' 48-72' 2448' 24' 8-10 <2 
vancomycin SOOmg 6' 48-72' 2448' 2448' >25 < 10 
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DISCUSSION 
Prediction of clearance rates 
In case of CA VH, the clearance rate is the product of the sieving coefficient and the 
rate of ultrafiltration. The latter is detennined by the trans membrane pressure 
difference, which depends on operational conditions, and on the hydraulic 
petmeability of the dialyzer, which decreases over lime. Therefore, even for a given 
dialyzer, the clearance rate by CA VH is quite variable. It can, however, easily be 
estimated from the sieving coefficient and the rate of ultrafiltration. 
Clearance by CA VHD, on the other hand, is detennined by convective and 
diffusive transpon. Diffusive transport is detennined by the concentration gradient 
between blood and dialysate and the mass transfer coefficient of diffusion. Moreover, 
at high dialysate flow rates the mass transfer coefficient of diffusion is increased. A 
high ultrafiltration rate implies a high hydraulic permeability, which is associated 
with a high diffusive permeability, thus a high K, value. Furthermore, the value of 
K, corrected for operational conditions depends on the solute molecular weight 
Therefore, it can be concluded that a mathematical model is required to estimate drug 
clearance by CA VHD. The use of the prediction formulas of K, of creatinine, 
together with the ratio of K, of drugs to that of creatinine as introduced in Chapter 
8, resulted in a fairly accurate estimation of the clearance rate of drugs. 
Furthermore, one can use this prediction model to estimate the clearance rate of 
other drugs or of solutes used in case of self-poisoning. The molecular weight and 
protein binding are input parameters and, when an indication is needed for the 
contribution of CA VHD to the total clearance rate, the endogenous clearance rate and 
the volume of distribution has to be known. 
Dose adjustments 
Dose adjustments of antibiotics are usually necessary for anuric patients, especially 
when clearance in these patients is low compared to that in normal subjects. If these 
patients are treated by CA VHD, the dosage regimen may be adjusted again. One 
might detennine drug clearance by CA VHD in individual cases and detennine drug 
dosage accordingly. For clinical practice, however, it is more convenient to use 
standard dosage regimens for patients treated by CA VHD, based on average 
clearance rates by CA VHD. Moreover, if one use such dosage regimens, a possible 
delay in lime of establishing the desired plasma levels of the drug will be avoided. 
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In this study, we calculated dosage regimens to be used for anuric patients treated 
by CA VHD. The averaged observed values of drug clearance rateS, used to calculate 
these dosage regimens, were approximately equal to the values of drug clearance 
rateS, predicted by taking an average value of ultrafiltration flow rate and membrane 
index. Therefore, it is concluded t.'Jat the calculated dose adaptations are based on 
average operational ccnditions. For each drug, the effect of the calculated dose 
adaptation on the plasma drug ccncentrations was ccnsidered when using input 
values of the drug clearance rate by CA VHD higher and lower as the averaged value. 
It was ccncluded that a ccnsiderable deviation in drug clearance rate by CA VHD 
from the value of the averaged clearance rate cculd take place before the 
reccmmended dose regimens were no longer appropriate. We used literature data on 
values of the volume of distribution measured in normal subjects. There have been 
several reportS in the literature on changes in distribution volume in intensive care 
patients [14-18]. Data are still to scarce, however, to determine whether and to what 
extent appreciable changes really occur. 
When ccnstructing treatment regimens, the dose-efficacy relationship of 
antibiotics [10-12] and toxicity of certain antibiotics has to be regarded. 
Killing of bacteria by beta-lactams is time dependent [12]. Furthermore, there 
is no ccncentration dependent killing above the MIC. These killing characteristics of 
beta-lactams would demand sustained concentrations above the MIC of the infectious 
organism. In animal models, ccntinuous serum ccncentrations above the MIC of the 
infecting organism have been shown to be more efficacious, ccmpared to transient 
peaks [11, 19]. Also, clinical outccme has been shown to be ccrrelated to the time 
above the MIC of the infecting organism [20]. Therefore, for these antibiotics, we 
aimed for plasma levels continuously above the MIC of most common pathogens. 
In contrast to beta-lactams, aminoglyccsides do show concentration dependent 
killing activity on Gram-negative aerobes [10] and killing is relatively fast. This has 
been shown in vitro [21] as well as in vivo studies [22]. High peak ccncentrations 
have been found to be a major determinant of clinical response [23]. Furthermore, 
aminoglyccsides show a postantibiotic effect against staphylococci as well as against 
vatious Gram-negatives [24, 25]. Vogelman et al [13] found a reduction of efficacy 
when the dosing interval was longer than the time period duting which the serum 
levels exceeded the MIC plus the duration of the postantibiotic effect. Several studies 
conclude that the AUC is the main determinant of efficacy [13, 26]. Apart from 
efficacy, toxicity is an Important issue. Nephrotoxicity, as well as oto- and 
vestibulotoxicity are major side-effects of aminoglyccsides. Aminoglyccsides are 
actively transponed into the proximal tubular cells, and this transpon is saturable [27, 
28]. These findings have led to a decreased dosing frequency in the last few years 
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[29]. When reconstructing a dosage regimen of aminoglycosides during treatment by 
CA VHD, we considered these factors. Thus, we paid particular attention to trough 
levels low enough to minimize toxicity, and the dosing interval was increased rather 
than the dose was lowered. 
The quinolones { ciprofloxacin) have a concentration dependent killing. 
Therefore, priority was given to high peak levels and a long dosing interval [12]. 
The most important finding of this study is that for cefuroxime, ceftazidime, 
tobramycin and vancomycin, the dosage regimen, used for anuric untreated patients, 
must be changed when the patient are treated by CA VHD. Failure to recognize this 
may easily lead to suboptimal drug levels and therapeutic failure. For the same 
reason, when there are alternative drugs of choice, clinicians may prefer drugs for 
which the influence of CA VHD on plasma levels can be neglected. Cefotaxime, 
imipenem and ciprofloxacin needed no dose adaptation during CA VHD. This was 
due to the relatively high non-renal clearance rates of these drugs, compared to that 
of CA VHD. It should be pointed out that the dosage regimens are theoretically 
derived from data obtained by a number of different studies. Although these dosage 
regimens are currently used in the clinic, the validity of these regimens needs 
confumation. In the future, studies have to be performed to determine plasma drug 
levels over time with the present dosage recommendations. 
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CLEARANCE OF IMIPENEM/CILASTATIN IN ACUTE 
RENAL FAILURE PATIENTS TREATED BY CONTINUOUS 
ARTERIOVENOUS HEMODIAFILTRA TION• 
INTRODUCTION 
The antibiotic Tienam• (MSD!USA) is the combination of imipenem, a broad 
spectrum thienamycin antibiotic belonging to the antibiotic class of carbapenem, and 
of cilastatin, an inhibitor of renal dehydropeptidase-1, the enzyme responsible for the 
metabolism of imipenem in renal tubular cells. The addition of cilasratin serves both 
to prevent nephrotoxicity by imipenem and causes the intact drug to be excreted into 
the urine [1, 2]. Although imipenem and cilastatin differ with respect to protein 
binding, their volumes of distribution and routes of metabolism, their plasma half 
lives are quite similar in normal subjects. lmipenem/cilastatin is often used in patients 
with acute renal failure due to sepsis. In case of renal failure, however, the plasma 
half life of imipenem is linle altered whereas that of cilastalin is vety much 
prolonged. It would seem questionable, therefore, whether the use of the fixed dose 
combination is justified in these patients. In Chapter 9, results of the rate of removal 
of imipenem and cilastatin with continuous arteriovenous hemodiafiltration were 
given. In this chapter, the consequences of using imipenem/cilastatin in a fixed dose 
combination are analyzed in patients with renal failure when untreated and when 
treated by continuous arteriovenous hemodiafiltration. 
METHODS 
The clinical and study protocols are described in Chapter 8. Analysis and calculations 
of these data were described in Chapters 8 and 9. Data of clearance rates of 
imipenem and cilastatin were compared and consequences of using these drugs in a 
fixed dose combination were considered. Concentrations in lime of imipenem and 
cilastalin were calculated for acute renal failure patients untreated and treated by 
CA VHD at a dialysate flow rate of 1 L/hr and 3 L/hr. Average values of drug 
distribution volume, clearance rates in normals and in anuric patients and plasma half 
• ReprinTed in revised fonn from Intensive Care Med. 1992, 18: 282-285 
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Table 1: Pharmacokinetics of imipenem and ci/astatin. 
1 Data taken from litera hire. 
2 Sum of non-renal clearance rate and average clearance by CAVH and CAVHD. 
3 Calculated by using Eq. 3, Chapter 9 (body weight 70 kg). 
Drug V,' [L/kgl Clearance [mVmin]: 
normal1 anuric1 an uric an uric an uric normal 
CAVH' CAVHD CAVHD 
I L/hr' 3 L/hr'' 
imipenem 0.31 245 116 125 134 149 1.0 
cilastatin 0.24 230 3 9 13 21 0.9 
Calculated half life [hrs]3 References 
an uric an uric an uric an uric 
CAVH CAVHD CAVHD 
I L/hr 3L/hr 
2.2 1.9 1.9 1.7 [3-6] 
89 21.6 14.9 9.2 [3, 6-9] 
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lives were taken from the literarure (see Chapter 9). Time related changes in drug 
concentrations were calculated according to: 
c =C .~v. 
P, Po 
(I) 
where Cp0 is the initial plasma concentration, C"' is the plasma concentration after a 
time span t after a dose application, and Cl is clearance rate. Literarure data on 
volume of distribution, normal and anuric clearance rates were combined with the 
average clearance rates by CA VHD to construct plots of plasma drug concentrations 
in time for imipenem and cilastatin. 
Results are given as average ± SD. 
RESULTS 
The average clearance by CA VH (i.e. at zero dialysate flow rate) was 7 ± 3 ml/min 
(range 4-12) for imipenem and 6 ± 2 ml/min (range 2-9) for cilastatin. Results of 
clearance rate by CA VHD were already presented in Chapter 9. The implications of 
the observed clearance rate by CA VHD for total drug clearance rates and half lives 
of both imipenem and cilastatin are presented in Table 1. From this Table one can 
see that treatmem of the anuric patient with CA VHD at Q. 1 or 3 L/hr increases the 
clearance rate of intipenem by 15% or 25% and that of cilastatin by 335% or 600% 
respectively. 
The usual dosage of Tienam• in our hospital is one intravenous dose (500 mg 
of intipenem + 500 mg of cilastatin) 4 times daily. Since, in patients with renal 
failure, the half-life of imipenem increases from 1.0 to 22 hrs, it was suggested in 
Chapter 9 that the dose interval in these patients should be doubled, i.e. one dose 
twice daily. The decrease of the half-life ofintipenem by CA VHD is relatively small. 
Therefore, during CA VHD, no further dose adjustment is deemed necessary. Half 
live of cilastatin however, increases in patients with renal failure from 0.9 to 89 hrs. 
With the above dosage regimens, it was calculated by using Eq. 1, that plasma 
concentrations of imipenem and cilastatin run parallel in normal subjects (Figure 1). 
In patients with renal failure, before treatment with CA VHD, cilastatin accumulates. 
Over 5 days, a seven fold increase in plasma concentrations may be expected to 
occur (Figure 2). After institution of CA VHD, there is a four fold increase of the 
clearance rate of cilastatin and plasma concentrations decrease to approximately two 
times the concentration in normal subjectS (Figure 3). Indeed, plasma concentrations 
of cilastatin ranged from 37-75 mg/L on the first day of CA VHD treatment and from 
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13-49 mg/L thereafter. These concentrations depend on the duration of the treatment 
with imipenem/cilastatin, the duration of the treatment by CA VHD and the time-span 
between administering the drug and taking the blood sample. 
200 
Cone. m /1 
175 
150 
125 
100 
75 
50 
0 2 3 4 5 
Day~.; 
Figure 1. Plasma concentration of imipenem and cilastatin in time in normal 
subjects. 
200 Cone. m /1 
175 
150 
Days 
Figure 2. Plasma concentration ojimipenem and cilastatin in time in anuric patients 
without renal replacement therapy. 
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200 Cone. m /1 
175 
Days 
Figure 3. Plasma concentration ofimipenem and cilastatin in time in anuric patients 
in whom CAVHD treatment is started 5 days after initiating drug 
treatment. 
(With imipenem, plasma levels calculated for dialysate flow rates of 1 Llhr 
and of 3 Ll hr are indistinguishable.) 
DISCUSSION 
For CA VH and CA VHD high flux membranes, such as AN-69, polysulfone and 
polyamide, are used. With these membranes solutes of up to several thousands 
Daltons, can freely pass thtough the membrane pores but proteins can not In Chapter 
8, it was shown that, at least with AN-69, the apparent sieving coefficient of a thug 
equals its non-protein boWld fraction. Accordingly, our data indicate that protein 
binding of imipenem (MW 317) was 0% and that of ci1astatin (MW 384) was 30%. 
These values, determined in intensive care patients, are considershly lower than those 
reponed for normal subjects, i.e. 20% for imipenem and 44% for cilastalin [3]. 
Dosage regimens of imipenem/cilastalin are based only on desired levels of the 
antibiotic imipenem. In the anuric state, even after dose adjustment, the use of the 
fixed dose combination will lead to an overdosage of cilastatin. Although no evident 
toxicity of cilastalin has been reponed so far [1, 3], the inevitable accumulation of 
this thug is to be regarded as undesirable. After hemofiltralion or dialysis treatment 
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is instituted, however, accumulation of cilastatin may be reversed, depending on the 
type of treattnent. This is caused by the contribution of such treattnent to the total 
drug clearance, which is proportionally greater for cilastatin than for imipenem. 
With CA VHD, at a dialysate flow rate of ouly I L/hr, the clearance rate will be 
twice as high as with CA VH due to the addition of diffusive transport. Serious 
accumulation of cilastatin is thereby avoided. In case of continuous vena-venous 
hemofiltration (CVVH), an ultrafiltration flow rate of 1200 ml/hr would be needed 
to achieve clearance rates similar to those obtained by CA VHD. In view of the above 
considerations, for patients with renal failure, who are treated with CA VHD, the use 
of the fixed dose combination of imipenem/cilastatin may be justified. 
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ACUTE RENAL FAll..URE IN INTENSIVE CARE 
PATIENTS: A FOLLOW UP OF 236 PATIENTS TREATED 
BY CONTINUOUS ARTERIOVENOUS 
HEMODIAFTI...TRATION OR INTERMITTENT 
HEMODIALYSIS 
IN1RODUCTION 
In the Second World War, monality of acute renal failure amongst woWlded 
servicemen was reponed to be 91% [1). Immediately upon the introduction of 
hemodialysis in 1942 by Kolff, monality of post surgical tubular necrosis decreased 
to 50.60% [1). Monality rates of critically ill patieots, however, have remained very 
high. Explanations for these high monality rates may be that nowadays patieots are 
older, more complicated surgery is performed and severely ill patients, who, in prior 
years, would not have survived, may develop reoal failure [2,3). Indeed, according 
to vatious studies, monality rates of critically ill patients with acute reoal failure 
range from 58% to 89% [4-9]. Differences between these figures are related to the 
need of reoal replacement therapy and 'co-morbidity'. 
After the introduction of contiouous methods of dialysis, a number of studies 
were performed to examine whether this teclmique may improve survival Bartlett et 
al found a survival rare of 12% in patients treated by intermittent hemodialysis and 
a survival rate in 28% in patients tteated by contiouous dialysis but this was not a 
statistically significant difference. A positive caloric balance did significaruly improve 
the outcome. Therefore, he concluded that, as with contiouous methods a positive 
caloric balance was easier to obtain, this method was to be preferred [9, 10]. Weiss 
et al recorded a 45% survival rare of patients treated with CA VH [11). McDooald 
et al, described in their retrospective study a trend of decreasing monality from 85% 
to 72% in patients, who needed dialysis treatment, after introduction of CA VHD 
[12). Kierdorf described in his randomized retrospective study a significantly lower 
survival rate of 78% of patieots treated by contiouous venovenous hemofiltration 
(CVVH) compared to a survival rare of 93% of patieots treated by imermitteru 
hemodialysis [13). However, compatisons of outcome are always frustrated by the 
heterogeneousness of the patient groups and the quality of medical care in general. 
Several studies describe the influence of clinical parameters on outcome. Corwin 
et a1 found that the presence of sepsis and non-recovery of renal function were 
important predictors of death [8). The factors of old age, sepsis and gastrointestioal 
128 
Chapter 11 
disease were associated with a poor prognosis in the study of Routh eta! [14]. Lobr 
et a! found fatal outcome to be related to a systolic blood pressure lower than 110 
m.mHg at the stan of dialysis [15]. Furthermore, Lien et a! demonstrated that among 
15 patients with hypotension for more than one week, who were treated by IHD, 
none survived [16]. In their stody, hypotension was defined as to exist when 
inotropic agents were necessary to maintain adequate blood pressure support. 
In the University Hospital Dijkzigt, before 1984, acute renal failure used to be 
treated by interminent methods. In case of severe hemodynamic shock, no dialysis 
treatment could be given at all. Continuous arteriovenous hemofiltration (CA VH) and 
hemodiafiltration (CA VHD) were first introduced in 1984 and 1986 respectively. 
With these techniques virtually all patients with acute renal failure could be treated. 
In this chapter, the clinical outcome is presented of 236 intensive care patients with 
acute renal insufficiency who received dialysis treatment. A ctitical condition of the 
patient never precluded dialysis treatment, but did influence the choice of a specific 
dialysis technique, i.e. intennittent hemodialysis or CA VHD. As the choice of the 
dialysis technique depended on the condition of the patient, the effect of treatment 
modality on mortality cannot be determined. We did compare duration of renal 
insufficiency and clinical outcome for patients with renal failure of different 
etiologies. 
METHODS 
Between 1985 and 1991, 236 patients with acute renal insufficiency received renal 
replacemem therapy. Acute renal insufficiency was diagnosed if the patiem had 
remained anuric for more than 24 hours and/or if serum creatinine concemralion had 
risen at least two-fold to more than 700 pmol/L. lf, at this stage, no spontaneous 
improvement was expected, renal replacement therapy was started. Eighty-nine 
patients were treated by intennittent hemodialysis (IHD) and 147 patients were 
treated by CA VHD. No patient with pre-existing chronic renal failure was included. 
Patients were treated with CA VHD in case of hemodynamic instability and/or 
neurological instability. A threatening respiratory failure, not due to fluid overload, 
was also an indication for treatment by CA VHD. Most patients treated by CA VHD 
required artificial ventilation as well as vasopressor support. 
CA VHD was performed as desctibed in Chapter 4. Intermittent hemodialysis was 
performed with a AN-69 plate dialyzer (Hospal) with a dialysate flow rate of 500 
ml/min, a blood flow rate of 100-150 ml/ntin and a sodium concentration in dialysate 
fluid of 140-145 m.mol/L. 
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PatieD!S were prospectively divided into four groups according to the clinical 
setting in which acute renal failure occurred: 
-A,: patieD!S with untractable shock (systolic pressure <100 mmHg at start of 
treannent). 
-A1: patients who had undergone aortic surgery or cardiac valve surgery. 
-A,.: patients who had been in shock, but whose blood pressure had now 
improved (including those who still had vasopressor suppon). 
-A3: patient with renal failure due to some tubulotoxic injury. 
Data on duration of renal failure and clinical outcome were collected. Renal function 
was taken to have recovered on the day of the last dialysis session. Patients, whose 
renal function had recovered, were followed for the time they were hospitalized, to 
determine monailty (from any cause) in this period, defined as 'late hospital death'. 
In patients treated by CA VHD, also the occurrence of sepsis and/or multi organ 
failure was recorded. Sepsis/MOF was diagnosed if the patient had a hemodynamic 
shock with low systemic vascular resistance, together with an infection and fever 
and/or a thrombocytopenia or multi organ failure of undetermined origin. 1bree 
patieD!S switched over to peritoneal dialysis, and from three patients, no data on 
follow up were available due to transfer to another hospital. Data of these patients 
were excluded from analysis. Statistical analysis was performed by using the Chi-
square test. Results are given as means ± standard deviation or, when appropriate, 
medians and range. 
RESULTS 
From 1985 to 1991, an increasing percentage of patients was treated with CA VHD. 
In 1991, 90% of all patients were treated by this method (Fignre 1). The age 
distribution of all patients is shown in Fignre 2. Mean age was 58± 7. Mean age of 
patients treated by CA VHD was not different from that of patients treated by IHD. 
Monailty was not related to age (Fignre 2). Data on recovery from renal function and 
survival for each patient group are given in Table 1. From the patients treated by 
CA VHD, 26% belonged to group A,, whereas this percentage was only 6% for the 
group of patients treated by IHD 
The duration of renal insufficiency is shown in Fignre 3. The duration of 
treannent for all patients was 8 days (range 1-71). For patients treated by IHD this 
value was 7 days (range 1-62) and for patients treated by CA VHD this value was 10 
days (range 1-71). Recovery of renal function occurred in 60% of all patients. Of 
patients treated by IHD 69% recoveted and of the patients treated by CA VHD 53%. 
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Table 2 shows p-values for recovery and survival for IHD, CA VHD and the 4 
different patient groups. Patient groups A, and A,. showed significantly higher values 
of recovery and survival compared to those of patient group A,. Figure 4 and 5 show 
recovery and survival rate of each diagnostic group. 
Overall patient survival rate was 44%. The survival rate of the group treated by 
IHD was 57% (n=86) and that of the group treated by CA VHD was 37% (n=l44). 
In patients who died, the period from starting dialysis treatment to death was 11 days 
(range 1-125). For patients treated by IHD this value was 10 days (range 1-96) and 
for patients treated by CA VHD this value was 13 days (range l-125). Late hospital 
death occurred more frequently in the group of patients treated by CA VHD compared 
to that treated by IHD (p =0.09). Patient group A, showed the highest rate (37.5%) 
and patient group A, showed the lowest rate (20%) of late hospital death. 
Table I. Outcome of patients treated by CA VHD or IHD. For definition of A0-A3 
see METHODS. 
CONTINUOUS ARTERIOVENOUS HEMOD!AFJLTRAT!ON 
n Died during Recovered from renal Late hospital death 
dialysis treatment function 
A, 37 23 14 6 
A, 27 13 14 7 
A, 70 27 43 10 
A, 10 4 6 1 
Total 144 67 n 24 
!NTERMIITENT HEMODIALYSIS 
n Died during Recovered from renal Late hospital death 
dialysis treannent function 
A, 5 3 2 0 
A, 34 15 19 3 
A, 29 7 22 3 
A, 18 2 16 4 
Total 86 27 59 10 
131 
Outcome 
Table 2: p-values calcuJated with the Chi-square test of differ em group of patiems. 
For abbreviations and definition of A0-A3 see METHODS. 
RECOVERY SURVIVAL 
GROUP p-va!ue p-value 
lliD vs CA VHD total group 0.03 0.005 
lliD vs CA VHD without sepsis/MOF 050 0.02 
lliD vs CA VHD with sepsis/MOF 0.007 0.006 
CA VHD; with sepsis/MOF vs without sepsis/MOF 0.11 0.95 
A, vs A1 0.!6 020 
A, vs A, 0.004 0.003 
A, VS A, 0.002 0.004 
A1 vs A, 0.20 0.10 
Al VS A3 0.08 0.07 
A, vs A, 0.07 058 
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Figure 1. Percentage of use of/HD and CAVHDfrom 1985 to 1991. 
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Figure 2. Age distribution of patients with acute renal failure treated by IHD or 
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Figure 3. Recovery of relUll junction of patients treated by IHD (1), patients treated 
by CAVHD without sepsis and/or MOF (II) and patients treated by 
CAVHD with sepsis and/or MOF (Ill). 
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Figure 4. Recovery of relUlljunction of each diagnosis group. For definition of A0-
A3, see METHODS. 
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Figure 5. Long-term survival of each diagnosis group. For definition of Ao-A3, see 
METHODS. Survival is defined as 'dismissed from hospital'. 
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Figure 6. Long-term survival of patients treated by IHD (1), patients treated by 
CAVHD without sepsis and! or MOF (II) and patients treated by CAVHD 
with sepsis and/or MOF (III). Survival is defined as 'dismissed from 
hospital'. 
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DISCUSSION 
It is generally agreed that in patients with acute renal failure mortality is caused by 
the underlying disease. This is borne out by a study by Mentzer et al, showing that 
a mortality rate of only 6% in 236 patients with post-operative acute tubnlar necrosis 
of a transplanted kidney [17]. Although mortality is a function of the underlying 
disease, the choice of renal replacement therapy may pethaps influence the outcome. 
In several Studies continuous dialysis tecbniques are recommended for the treannent 
of critically ill patients. However, no randomized or severity matched prospective 
study has been realized yet, to evaluate the superiority of either the interminent or 
the continuous mode of dialysis. 
Also this study cannot answer this question. Therefore, the first three p-values 
in Table 2 can only be used to value the bias in the choice of a specific dialysis 
technique. Indeed, from Table 2 and Figure 3 and 5, it is clear that patients treated 
by IHD have a significantly higher recovery and survival rate than patients treated 
by CA VHD. This difference is likely to be due to the large group of patients with 
sepsis/MOF, treated by CA VHD. However, a statistically difference between 
recovery or survival rateS of patients treated by CA VHD with or without sepsis/MOF 
conld not be detennined. OtheiS found that presence of sepsis was related to survival 
[8, 14, 18], but Lien et a! demonstrated that !he presence of sepsis was not 
significantly different between survivors and non-survivoiS [16]. That we found no 
difference in outcome of our patients with or without sepsis/MOF may be explained 
by the critical illness of all patients treated by CA VHD, which accounts for high 
mortality rates, even in absence of sepsis or MOE This is confirmed by the 
statistically higher survival rate of patients treated by IHD compared to patients 
without sepsis/MOF, who are treated by CA VHD. Also, as 'late hospital death' 
occurred more frequently in patients treated by CA VHD, it can be concluded that 
these patients were more severely ill than patients treated by IHD. Fur!hennore, 
patients from group Ao were ptedominantly (88%) treated by CA VHD, indicating 
that CA VHD was used primarily for patients with poor condition. This is in 
accordance with the approach of our department to treat these patients preferably by 
CAVHD. 
In some studies it is reponed that mortality increases with age [7, 14, 19], but 
otheiS have not [20, 21]. Our resnlts did not show any relation of monality rate with 
age. 
This retrospective study does not answer the question whether the introduction 
of CA VHD has improved the prognosis of severely patients with acute renal failure. 
Evidence suggesting that prognosis in severely ill patients can be improved by 
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CA VHD, can be deduced from the observation that our patients with hemodynamic 
shock (A,), who were predominantly treated by CA VHD, showed a survival rate of 
24%. Lien et a! [16] described no survivors in patients with hypotension for more 
than one week, who were treated by IHD. In conclusion, from 230 intensive care 
patients with acute renal failure, a recovery rate of renal function of 60% and a 
patient survival rate of 44% was obtained. Compating these values with literature 
data, it can be concluded that these results are quite satisfactory. 
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SUMMARY 
Continuous aneriovenous hemodiafiltration (CA VHD) is a dialysis modality used to 
treat intensive care patients. 1n this thesis, the clinical use, the impact of illter design 
aod membrane aod the mechaoism of solute transpon of continuous aneriovenous 
hemodiafiltration (CA VHD) are described. 
A mathematical model of solute trangpon by combined convection and diffusion was 
developed aod applied to clinical aod laboratory data. From these data, a prediction 
model of clearance rates of uremic solutes and drugs was derived. Funhermore, the 
impact of clearance of drugs by CA VHD on dose adjusnnents was determined. 
Finally, the outcome of patients with acute renal insufficiency, treated by intermittent 
hemodialysis or CA VHD was described. 
Chapter 1: 
Chapter I gives a shon history of hemodialysis. Different mechanism of solute 
transpon aod terminology are discussed. 
Continuous aneriovenous hemoilltration (CA VH) and continuous aneriovenous 
hemodiafiltration (CA VHD) were imroduced in the Dijkzigt University hospital in 
1984 aod 1985 respectively. Continuous hemodialysis is performed 24 hours a day, 
like the human kidney, intermittent hemodialysis is performed just a few hours a 
day. CA VHD is characterized by the use of a small surface membrane with a high 
hydraulic permeability, a spontaneous blood flow obtained by the pressure difference 
between an anery and a vein, a spontaoeous ultrailltrate flow and a low dialysate 
flow rate of l-3 L/hr. 
Chapter 2: 
1n this chapter, a shon overview is given of clinical problems encountered with 
intermittent macltine-hemodialysis, with emphasis on the possible consequences for 
critically ill patients. 
The most frequent complication is dialysis-induced hypotension. Also, with 
neurologically unstable patients, intermittent hemodialysis may impair the 
neurological condition as a result of sudden changes in pH and osmolality. 
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Chapter 3: 
In this chapter, the indications for CA VHD are described. 
The most imponant indication for treatment by CA VHD is the combination of renal 
failure and circulatory instability. Neurological instability or the need for high 
clearance rates in severe catabolic patientS is another indication for treatment by 
CA VHD. Also, after kidney transplantation i11 a patient with primary hyperoxaluria, 
plasma oxalate levels can be kept low by using CA VHD. CA VHD is contraindicated 
if tile extracorporeal circuit interferes witil the mobilisation of the patient 
In tilis chapter, tile necessities are described and guidelines for application for tile 
techoique are given. 
Chapter4: 
For capillary hemofilters, tile resistance to flow may be predicted from tile filter 
geometry by using Poiseuille's law, assuming laminar flow. Blood viscosity can be 
calculated from hematocrit, protein concentration and temperature. However, 
observed filter resistance to flow was two to tilree times higher tilan tile predicted 
value. Comparison of actual blood viscosity witil tile calculated value showed tilat 
blood viscosity was grossly underestimated. Herewitil, pan of tile discrepancy 
between measured and predicted values could be explained. Further discrepancies 
between tilese values could be explained if tile fiber diameter would be a mere 8 % 
lower tilan tile value given by tile manufacturer. 
Chapter 5: 
Existillg models of hemodialysis are not likely to be useful for the analysis of solute 
transpon in CA VHD, as solute transpcn inCA VHD differs from tilat in ime!I!littent 
hemodialysis, The most impcnant differences are: 
l. Witil CA VHD, solute transpcn occurs by simultaneous convecrion and diffusion. 
2. Witil CA VHD, dialysate flow rates (10-30 ml/min) are very low compared to 
blood flow rate (100-250 ml/min). 
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3. CA VHD is a continuous technique. With prolonged use of the filter, 
deterioration of the membrane is likely not only to decrease the rate of 
nltrafiltration but also to impair diffusive mmspon. 
Therefore, a new mathematical model of combined convection and diffusion in 
CA VHD was developed. Three important assumptions were made: 
1. A homogeneously distribution of blood and dialysate over their respective 
compartmems. 
2. A constant membrane permeability for nltrafiltration and for diffusion over the 
eutire membrane length. 
3. No variations of solute concentration in the radial direction were considered, i.e. 
calcnlations are based on local "mixing cup" concentrations. 
Using this model, a numerical as well as an analytical solution of the mass transfer 
coefficient of diffusion (K,) conld be given. 
Chapter 6: 
In this chapter, the assumption of mixing cup concentrations in the model was 
validated. This assumption is valid when compartments are well stirred, a condition 
which can be approached if flows are turbulent. A radial concentration gradient can 
be influenced by axial flow rates. Blood flow rate had no measurable influence on 
the calcnlated value ofK.. Dialysate flow rates (Q,), however, did have an influence 
on K.· The calcnlated value of K. increased with increasing dialysate flow rates. This 
may be explained by the existence of an unstirred layer in the dialysate compartment, 
or, at low dialysate flow rates, the distribution of dialysate over the compartment is 
inadequate, resulting in a partial use of the membrane surface area. Also, K. proved 
to be dependent on the hydraulic permeability index of the membrane (MI). The 
relationship of K. with Q. and MI was quantified by a mathematical expression. 
Chapter 7: 
In this chapter the applicability of the prediction formulas of the mass transfer 
coefficient of diffusion (Kd) of creatinine, as derived in chapter 6, was eXatnined. It 
was concluded that 73% of the variability of Kd and 81% of the variability of the 
clearance rate of creatinine can be explained by variations in Qd and MI. The value 
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of plasma water flow rate at the filter inlet (Q,.i) is needed to predict clearance rate. 
This value is, like the value of MI. not readily available in the clinical setting. 
Therefore, nomograms were constructed to read esthnated values of Qwi from the 
mean arterial pressure (MAP) and esthnated values of MI from the MAP and the 
ultrafiltration flow rate. 
Chapter 8: 
In this chapter, we applied the model to the transport of drugs. Sieving coefficients 
of the drugs and the relation of K, and molecular weight of the drugs were examined 
for cefuroxime, cefotaxime, ceftazidime, imipenem, cilastatin, ciprofloxacin, 
tobramycin and vancomycin. 
Two important results were obtained. First, it was demonstrated that the sieving 
coefficient of the drug may be equated to its non-protein bound fraction, which may 
be detennined in the laboratory. Second, we found a fixed relationship berween the 
ratio of K, of drugs to that of creatinine and the molecular weight of the drug. 
Chapter 9: 
In this chapter, the feasibility of predicting clearance rates of drugs and consequences 
for dose adaptations were considered. The use of the prediction formula of Kd of 
creatinine, together with the ratio of Kd of drugs to that of creatinine resulted in a 
fairly accurate esthnation of the clearance rate of drugs. This esthnation is accurate 
enough to be used in the clinic. 
For each drug, dose adaptations were calculated based on average operational 
conditions. For anuric patients treated by CA VHD, dose adaptations were needed for 
cefuroxime, ceftazidime, tobramycin and vancomycin. Failure to recognize this may 
easily lead to suboptimal drug levels and therapeutic failure. For cefotaxime, 
imipenem and ciprofloxacin this was not needed. Therefore, the dosage regimens nf 
cefotaxim, imipenem and ciprofloxacin used for anuric patients, can also be used for 
anuric patients treated by CA VHD. 
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Chapter 10: 
TienamR is the combination of imipenem and cilastatin. When using this combination 
in patientS with renal failure, one should take imo account the more prolonged half 
life of cilastalin in comparison with that of imipenem. In the anuric state, even after 
dose adjusnnent, which is based on desired plasma levels of im.ipenem, the use of 
the fixed dose combination will lead to an overdosage of cilastatin. However, after 
institution of CA VHD, clearance rate of cilastalin increases four fold and serious 
accumulation of cilastalin is thereby avoided. 
Chapter 11: 
We studied the clinical outcome of 236 critically ill patients with acute renal 
insufficiency, who received dialysis treatment either by intermittent hemodialysis or 
CA VHD. In general, mortality rates of these patients are very high. In our patients, 
recovery rate of the kidney was 60% and survival rate of the patiem was 44%. 
Survival rate depended on the clinical setting in which acute renal failure was 
acquired, or the clinical condition of the patient at start of the dialysis treatment 
Death after recovery of renal function occurred more frequently in the group of 
patients treated by CA VHD. This suggests, that patients treated by CA VHD were 
more severely ill than patients, who could be treated by intermittent techniques. 
Patients with umractable shock at start of dialysis treatment were predominantly 
treated by CA VHD and showed a survival rate of 24%. Before the intrOduction of 
CA VHD, dialysis could hardly be performed in such patients. Therefore, from this 
observation it may be deduced that prognosis of these severely patients was improved 
by the intrOduction of CA VHD. 
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Continue anerioveneuze hemodiafiltratie (CA VHD) is een dialyse teclmiek die 
gebruilct wordt voor de behandeling van patiemen met nierinsufficientie die verpleegd 
worden op een intensive care afdeling. In dit proefschrift is het klinisch gebruik, de 
invloed van de kunstnier op het slagen van de behandeling en het mechanisme van 
massatransport bij CA VHD beschreven. 
Een wiskundig model van massatranspon bij het bestaan van een gelijktijdig 
convectief en diffusief transport werd onlwikkeld en meetresultaten verkregen in de 
kliniek en hetlaboratorium werden hiennee geanalyseerd. Gebaseerd op deze analyse 
kon een model onlwikkeld worden ten behoeve van de voorspelling van de klaring 
van uremische stoffen en geneesaniddelen. Tevens werd de noodzaak. tot aanpassen 
van de dosis van diverse geneesmiddelen als gevolg van de klaring door CA VHD 
bestudeerd. Ten slotre zijn het herstel van nierfunctie en monaliteit beschreven van 
een groep patienten met acute nierinsufficientie, die behandeld werden met 
intennitterende hemodialyse of CA VHD. 
Hoojdstuk 1: 
In dit hoofdstuk wordt in het kart de historie van de hemodialyse beschreven. Oak 
worden de verschillende mechanismen van massatransport en de bijbehOrende 
tenninologie behandeld. 
Continue anerioveneuze hemofiltratie (CA VH) en continue anerioveneuze 
hemodiafiltratie (CA VHD) werden respectievelijk in 1984 en 1985 gelntroduceerd 
in het Academisch ziekenhuis Dijkzigt te Rotterdam. Continue dialyse wordt, 
overeenkomstig de menselijke nier, 24 uur per dag uitgevoerd; intennitterende 
dialyse daarentegen wordt enkele uren per dag uitgevoerd. CA VHD wordt 
gekarakteriseerd door het gebruik van een membraan met een klein oppervlak en een 
hoge hydraulische permeabiliteit, een spontaan op gang gebrachte bloed stroom 
middels het dtukverschil tussen een anerie en een vene, een spontane ultrafiltratie 
stroom en een !age dialysaat stroomsnelheid van 1-3 L/uur. 
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Hoofdstuk 2: 
In dit hoofdstuk wordt een kart overzicht gegeven van klinische problemen zoals die 
kunnen ontstaan tijdens behandeling met intennitterende hemodialyse. Hierbij is de 
nadruk gelegd op de mogelijke consequenties voor patienten die verpleegd worden 
op een intenSive care afdeling. 
De meest voorkomende complicatie tijdens dialyse is hypotensie. Ook kan, door 
te plotselinge veranderingen in de pH en de osmolariteit van het bloed, de 
neurologische toestand van een neurologisch reeds instabiele patiem verslechteren. 
H oofdstuk 3: 
In dit hoofdstuk komen de indicaties voor de behandeling met CA VHD aan bod. De 
belangrijkste indicatie voor behandeling met CA VHD, is de combinatie van nierfalen 
en circulatoire instabiliteit. Overige indicaties zijn een neurologische instabiliteit of 
de behoefte aan hoge klaringssnelheden bij ernstig katabole patienten. Ook kan met 
behulp van behandeling met CA VHD de plasma spiegel van oxalaat van een patient 
met primaire hyperoxalurie voldoende laag gehouden worden na een 
niertransplantatie. CA VHD is gecontraindiceerd als het extracorporele circuit 
interfereert met de mobilisatie van de patient. 
Verder worden in dit hoofdstuk de benodigdbeden en een leidraad voor het gebruik 
voor CA VHD beschreven. 
Hoofdstuk 4: 
Als men aanneemt dat er sprake is van een laminaire bloedstroom, kan de 
stromingsweerstand van capillaire hemofilters voorspeld worden met behulp van de 
wet van Poiseuille. De viscositeit van bloed kan berekend worden uit de waarde van 
de hematocriet, de eiwit concentratie en de temperaruur. Echter, de waarde van de 
geobserveerde strcmingsweerstand van het filter was twee tot drie keer zo hoog dan 
de door ons voorspelde waarde. Vergelijking van de waarde van de gemeten 
viscositeit van bleed met de berekende waarde liet echter zien dat de gebruikte 
berekening van de viscositeit in een te !age waarde resulteerde. Een dee! van de 
discrepantie tussen de geobserveerde en berekende stromingsweerstand kon hiennee 
verklaard worden. De overblijvende discrepantie russen de berekende en gemeten 
waarde van de sttomingsweerstand kon worden verklaard door de i.'l.terne diameter 
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van de capillairen van bet filter 8% lager aan te nemen dan door de fabrikant wordt 
opgegeveo. 
Hoofdstuk 5: 
Reeds bestaande modellen van bet massarransport tijdens hemodialyse kunnen niet 
gebnrikt worden voor de analyse van het massatnmsport tijdens CA VHD. Redenen 
biervoor zijn dat het tnmsport tijdens CA VHD verscbilt met bet transport tijdens 
hemodialyse. De belangrijkste verschillen zijn: 
1. Massatransport bij CA VHD vindt plaats middels gelijktijdige convectie en 
diffusie. 
2. Stroomsnelheden van dialysaat (10-30 ml/min) bij CA VHD zijn erg laag 
vergeleken met StroOmsnelbeden van bloed (100-250 ml/min). 
Ook zou de Stroomsnelheid van bet dialysaat te laag kunnen zijn om een 
optimale distribu1ie van het dialysaat in bet dialysaat-compardment te 
bewerlcstelligen. 
3. CA VHD is een con1ioue techniek. Door bet langdurig gebruik van eenzelfde 
membraan, ligt het niet alleen voor de band dat de ultrafiltratie stroomsnelheid 
afneemt in de 1ijd, maar ook dat het cliffusieve tnmsport zou kunnen afnemen in 
de tijd. 
V anwege deze verschillen werd een nieuw wiskundig model, toepasbaar op de 
situatie bij CA VHD, van gecombineerde convectie en cliffusie ontwikkeld. Hierbij 
zijn drie belangri jke aannamen gedaan: 
1. De distributie van bloed en dialysaat in de respectieve compardmenten is 
bomogeen. 
2. De permeabiliteit voor ultrafiltratie en diffusie is over de gebele lengte van de 
membraan constant. 
3. Variaties in concentraties in de radiale ricbting werden niet in bescbouwing 
genomen, bierdoor werden de berekeningen dus gebaseerd op lokale "mixing 
cup" concentraties. 
Met dit model kon een numerieke en een analytische afieiding van de massatransport 
coefficiem voor diffusie (K,) gegeven worden. 
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Hoofdstuk 6: 
In dit hoofdstuk werd de aanname 'de aanwezigheid van "mixing cup" concenttaties' 
gevalideerd. Deze aanname is valide, als de inhoud van de compartimenten 
homogeen zijn, een conditie die benaderd kan worden als de stromen twbulent zijn. 
Een radiale concentratie gradient kan beiilvloed worden door axiale stroomsnelheden. 
De stroomsnelheid van bloed had geen meetbare invloed op de waarde van de K,. 
De stroomsnelheid van dialysaat (Q,) had echter wei een invloed op de waarde van 
de K,. Dit kan verldaard worden door het bestaan van een grenslaag in het 
dialysaatcompartiment, of, bij lage dialysaat stroomsnelheden, door een inadequate 
distributie van het dialysaat over het gehele compartiment wat resulteen in het 
gebruik van slechts een gedeelte van het membraanoppervlak. Oak bleek de K, 
afhankelijk te zijn van de hydtaulische permeabiliteit index van de membraan (MI). 
De vastgestelde relatie tussen de K, met de Q. en MI werd uitgedrukt in een aantal 
formoles. 
Hoojdstuk 7: 
In dit hoofdstuk werd de bruikbaarlJ.eid van de formules, zoals afgeleid in Hoofdstuk 
6, getoetst voor het voorspellen van de massatransport coefficient voor diffusie van 
creatinine. Het bleek dat voor creatinine 73% van de variabiliteit in de K, en 81% 
van de variabiliteit in de klaring verldaard kon worden door variaties in de Q. en MI. 
Om de klaringssnelheid te voorspellen moet de waarde van de stroomsnelheid van 
plasma water (Q..,) bekend zijn. Deze waarde is, evenals de waarde van de MI, in de 
klinische situatie niet direct voorhanden. Daarom werden nomogrammen 
geconstrueerd, waarin waarden van Qwi afgelezen kunnen worden met gebruik van 
de waarde van de gentiddelde arteriele druk en waarden van MI afgelezen kunnen 
worden met gebrnik van de waarde van de gentiddelde arterie1e druk en de 
stroomsnelheid van ultrafiltratie. 
Hoofdstuk 8: 
In dit hoofdstuk werd het transportmodel toegepast op transport van geneesntiddelen, 
i.e. antibiotica De "sieving" coefficienten van de geneesmiddelen en de relatie tussen 
de K, en het molekuul gewicht werden onderzocht voor cefuroxim, cefotaxim, 
ceftazidim, intipenem, cilastatine, ciprofloxacine, tobramycine en vancomycine. 
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Hiermee werden twee belangrijke resultaten verkregen. Ten eerste, de "sieving" 
coefficient mocht gelijk gesteld worden aan de vrije fractie van het antibioticum, 
welke laatste gemeten kan worden in het laboratorium. Ten tweede, er bleek een 
vaste relatie te bestaan russen de ratio van de :£<. van de antibiotica t.o.v de K, van 
creatinine met het molekuul gewicht van het antibiotica 
H oojdstuk 9: 
In dit hoofdstuk werd de mogeli jkheid onderzocht of de klaringssnelheid van 
antibiotica door CA VHD voldoende betrouwbaar te voorspellen was. Het gebruik van 
de voorspellingsformule van de K. van creatinine tezamen met de ratio van de :£<. 
van het antibioticum t.o.v. de Kd van creatinine, leverde een zodanige voorspelling 
van de klaringssnelheid van deze antibiotica op, dat deze klinisch geed bruikbaar is. 
Tevens werd onderzocht of deze klaring consequenties heeft, zodanig dat het 
doseringsschema van een patient die met CA VHD behandeld word!, veranderd moet 
worden. Doseringsaanpassingen, gebaseerd op gemiddelde condities van de kunsmier, 
werden berekend voor elk gemeten antibiotica. Het bleek, dat voor patienten met 
anurie die behandeld werden met CA VHD, een doseringsaanpassing nodig was bij 
het gebruik van cefuroxim, ceftazidim, tobramycine en vancomycine. Als aanpassing 
van de dosering tijdens behandeling met CA VHD wordt nagelaten, kunnen te !age 
antibiolicaspiegels met daarbij falen van de antibiotische lherapie zeer wei mogelijk 
zijn. Bij het gebruik van cefotaXim, hrlipenem of ciprofloxine werd deze aanpassing 
rliet noodzakelijk geacht. Bij gebruik van deze laatst genoemde geneesmiddelen kan 
voor een anurische patient die behandeld wordt met CA VHD, hetzelfde 
doseringsschema gebruikt worden als dat voor anurische patienten, die rliet 
gedialyseerd worden. 
Hoofdstuk 10: 
Het geneesmiddel TienamR is een combinatie van 500 mg imipenem en 500 mg 
ciJastatine. Als men dit geneesmiddel gebnlikt bij palienten met anurie, moet men 
rekerling houden met het feit dat de halfwaardetijd van ciJastatine in vergelijking met 
imipenem sterker verlengd is. Als de patient anurisch is, wordt een aangepaste 
dosering gebruikt, berekend op gewenste spiegels van hrlipenem. Dit leidt tot een 
overdosis van cilastatine. Echter, als deze patient behandeld wordt met CA VHD, zal 
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de klaringssnelheid van cilastatine vietvoudig toenemen en daardoor wordt emstige 
accumulatie van cilastatine venneden. 
Hoofdstuk 11: 
In dit hoofdstuk is het herstel van de nierfunctie en de monaliteit bestudeerd van 236 
patienten met acuut nierfalen die behandeld werden op een intensive care afdeling. 
Deze patienten werden ofbehande1d met intennitterende dialyse of met CA VHD. In 
bet algemeen is de monaliteit van deze patienten erg hoog. Bij de besclrreven groep 
patienten herstelde de nierfunotie in 60%. Het overlevingspercentage was 44%. Het 
percentage van overleving was gecorreleerd met de onderliggende ziekte of met de 
klinische toestand van de patient bij aanvang van de dialyse behandeling. De groep 
patienten die met CA VHD werden behandeld hadden een hogere monaliteit na 
herste1 van de nierfunotie. Dit impliceen dat patienten die een behandeling ntiddels 
CA VHD kregen, zieker waren dan patienten die een behandeling ntiddels 
intermitterende hemodialyse konden ondergaan. Van de patienten, die bij de aanvang 
van de dialysebehandeling in een onbehande1bare hemodynantische shock verkeerden, 
overleefden 24%. Deze patienten werden voornamelijk gedialyseerd ntiddels 
CA VHD. In het verleden, voor de introduotie van CA VHD, konden deze patienten 
niet of nauwelijks een dialyse behal1deling verdragen. Hieruit zou men voorzichtig 
de conclusie kunnen trekken dat het gebruik van CA VHD, voor deze emstig zieke 
patienten een verbetering van hun overlevingskansen heeft gegeven. 
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NAWOORD 
Dit proefschrift is het resultaat van een samenwerlcingsproject tussen de afdelingen 
Interne Geneeskunde I en Biomedische Natuwkunde en Technologie van de Erasmus 
Universiteit Rotterdam. Velen hebhen hieraan hun medewerlcing verleend. Zonder 
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manuscript is voor mij van grote waarde geweest Prof. Dr. W.A Weimar en Dr. 
R T. Krediet wil ik bedanken voor het kritisch lezen van het manuscript en hun 
waardevolle commentaar. 
Een hardwerkende en vooral gezellige onderzoeksgroep was de basis waarop dit 
proefschrift kon ontstaan. 
Dr. H.H. Vincent, tnijn directe hegeleider, vettegenwoordigde hierin de klinische 
discipline, al was fysica hem niet vreemd en was de initiator van dit onderzoek. 
Beste Jeroen, je bent een "co-promotor'' van onschatbare waarde geweest. Je altijd 
goede humeur hoezeer ik ook 'een slabak van woorden' wist te creeren en je talent 
om alles altijd weer netjes op een rijtie te zetten heeft tnij enorm aangemoedigd. 
Jouw vermogen om een onderzoek op te zetten en de resultaten helder te 
interpreteren en formuleren, zal voor mij een voorbeeld blijven. De tomeloze energie 
die je op (en over) wist te brengen, heeft er mede toe geleid dat aan het eind van 
onze 216-jarige samenwerking dit proefschrift voor een groot dee! voltooid kon zijn. 
Na deze periode wist ik je per post. flop, fax of telefoon lastig te vallen, waardoor 
nog vele grote en kleine vragen tnijnerzijds beantwoord werden, waarvoortnijn dank. 
Ir. W.A. van Duyl vettegenwoordigde de hegeleiding van het fysische onderdeel 
van dit onderzoek. Beste Wun, met weemoed denk ik terug aan de vrijdagen van 11 
tot 1 en de altijd openstaande deur om fysische vraagsrukken door te nemen. Je 
kritische stem in de voortgang en analyse van het onderzoek, je aandacht en 
medeleven ook voor niet-wetenschappelijke problemen zijn onmisbaar geweest Ik 
wist je in je drukste lijd te overspoelen met telkens weer nieuwe hoofdstokken. maar 
toch vond je iedere keer weer de energie om er vee! aandacht aan te hesteden, 
waarvoor tnijn dank. 
Ir. E. Ak9alJuseyin was ons rekenwonder. Beste Emin, heerlijk waren die 
discussies met jou, of het nu fysica, poliliek, trouwen, Turldje of Nederland hetrof. 
Jouw vermogen om wiskundige afleidingen te creeeren is van groot belang geweest 
Zonder jouw "K," was dit proefschrift er dan ook niet geweest. Met veel geduld beb 
je me de essenlies van het transpOrt duidelijk gemaakt, waarvoor tnijn dank. 
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Hans de Bakker, bedankt voor je onmisbare technische steun lijdens de metingen 
en hulp bij het oplossen van vele problemen. De stagiaires Andre de Mol, Marco 
Poot en William Allheer dank ik voor hun aktieve en enlhousiaste uitvoetingen van 
de stromingsweerstand en flow metingen. 
Alle medewerkers van de afdeliog Dialyse dank ik voor hun enlhousiasme en 
medeleven en koffie. Hun bewaarzucht voor alles wat anders in de prullenbak was 
verdwenen, heeft vee! in-vitro proeven mogelijk gemaakt. Fons, jij bent een speciale. 
De puinhoop en bet waterballet die ik op jouw kamer mocht veroorzaken, zullen me 
nog lang heugen! 
De Intensive Care afdeliogen van het Dijkzigt ziekenhuis ben ik zeer erkentelijk 
voor het geduld en de medewerking tijdens mijn regelmatig urenlange aanwezigheid. 
De afdeliog Mediscbe Microbiologie, in bet bijzonder Johan Mouton, Ed 
Hzermans en Marius Vogel, wil ik bedanken voor de preuige samenwelking. Johan, 
ondanks mijn haast, mijn gebrek aan lijd en dat ik betliever gisteren dan vandaag 
af wilde hebben, beb je gelukldg de moed nooit opgegeven. 
Een ieder verder, die ik benaderd beb voor meedenken, luisteren en 
beantwoorden ofuitvoeren van alle mogelijke en onmogelijke vragen, wil ik op deze 
plaats hiervoor bedanken. 
De paranimfen Jolien Tuyl en Gerda Verpoorte ben ik nog vee! verscbuldigd 
voor de hulp bij het regelen van alles wat er bij een promotie komt kijken. Bedankt! 
Mijn huidige werkgever, de Maatscbap Artsen-microbioloog Brabant, wil ik op 
deze plaats bedanken voor de gelegenheid die zij mij bebben geboden om dit werk 
te voltooien. 
Hans, allebei in het "promotie-schuitje" en toch hebben we bet gezellig weten 
te houden! 
A an mijn ouders, die mi j geslimuleerd hebben om te studeren en vooral verder te 
gaan dan dat alleen, wil ik dit proefschrift opdragen. 
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